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Abstract 
 
An emerging concept in the regulation of signal transduction specificity is the mediation 
of scaffold proteins embedded in the circuitry of signalling pathways. The multidomain-
based architecture of scaffold proteins facilitates the assembly and modulation of protein 
complexes to regulate cellular signals to bring about an exacting biological output. The 
work presented in this thesis aimed to investigate the mechanisms of the protein scaffold 
CNK1 (connector enhancer of Ras 1) in the pro-apoptotic MST2 pathway and the pro-
oncogenic Raf-1 signalling pathways. Here, by using several molecular, biochemical and 
cell biology techniques, I demonstrated that CNK1 regulates the interaction of the proto-
oncogene Raf-1 and the tumour suppressor MST2 kinase. Perturbations of CNK1 levels 
exhibit a biphasic signalling response typical of a scaffold protein. Transient expression 
of CNK1 upon growth factor withdrawal results in a concentration-dependent increase 
of the Raf-1/MST2 complex, thus preventing apoptosis, but this complex dissociates at 
higher expression levels, hence promoting an apoptotic response. Moreover, CNK1 is 
involved in the regulation of Fas-induced apoptosis via the MST2/RASSF1A pathway 
by influencing the time-scale kinetics of MST2 docking and release from the Raf-
1/CNK1 complex and its eventual activation. SiRNA-silencing of CNK1 destabilizes the 
Raf-1 and MST2 interaction, and enhanced MST2/LATS1 interaction that promotes 
apoptosis. Thus, CNK1 is required for Raf-1 inhibitory function, but is also necessary 
for MST2-mediated apoptosis. Remarkably, CNK1 selects and switches complex 
formation of opposing anchored proteins depending on the stimulus. In response to Fas 
ligand stimulation, MST2 is released, whereas Raf-1 is retained in complex with CNK1. 
Conversely, CNK1 retains MST2 and whilst releasing Raf-1 from the complex following 
growth factor treatment. Mapping the multidomain binding sites of CNK1 using peptide 
array demonstrates specific interaction sites of client protein complexes. Specific CNK1 
point mutants were generated, and found to alter wild-type regulation of client protein 
complexes. Thus, the work described in this thesis may reveal a regulatory crosstalk 
between the MST2 apoptotic pathway and the Raf-1 proliferative pathway through 
CNK1 by coordinating assembly of appropriate pathway components to possibly drive 
discrete stimulus-specific responses.  
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1.1     Motivation 
 
 
The study presented here involved fundamental biological mechanisms that are 
characteristics of cancer. However, current knowledge is overwhelmingly enormous and 
complex, and more importantly new insights and discoveries are ever rapidly emerging. 
I therefore resolved to start with a general background on cancer and highlighting 
underlying biological processes relevant to this thesis. Next, signalling pathways 
involved with tumour suppressor MST2 and proto-oncogene Raf-1 were discussed 
leading to the overview of the scaffold protein CNK1 including current perspectives on 
scaffold proteins.    
 
 
1.1.1     Cancer 
 
 
Cancer is the second most common cause of death in the western world and accounts for 
about 13% of all human deaths worldwide. It is believed that increasing global cancer 
rates have been primarily due to an aging population and lifestyle changes in the 
developing world (Jemal et al., 2010). Cancer is an old and a very complex disease, or 
better yet a collection of diseases both at the molecular and system-wide level. The 
practices of classical biology have led to a realisation that the reductionist approach may 
not be adequate to explain the dynamics of complex biochemical systems within a cell or 
population of cells therefore introduces a bottleneck in the pursuit to understand cancer 
(Nurse, 2008). On the other hand, it is still extremely crucial in elucidating fundamental 
processes and an important tool for validation of new novel discoveries. Hence, from 
this realisation, the emergence of new fields of studies such as genomics, proteomics, 
systems biology and synthetic biology have sprung. Essentially, these are collaborative 
studies from different disciplines using high-throughput state-of-the-art tools to acquire 
new knowledge. The aim is to integrate collective complex data to advance the 
understanding of biological phenomena and to attempt in progressing treatment and 
prevention of diseases like cancer. While previously scientists have unravelled valuable 
knowledge of specific normal molecular functions, we are now beginning to understand 
better the intricacies and complexity of the mechanisms of normal cell regulation 
through cancer research (Gilbert and Sarkar, 2000; Rosenfeld and Kapetanovic, 2008). 
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Indeed, collaborative approaches with computer scientists and engineers that aim to 
understand the breakdown or failure of cell mechanics has been very fruitful in 
advancing biological research (Ideker et al., 2001; Zhong and Sternberg, 2007). It is 
perhaps also true in cell biology that by learning from failures of cellular regulation, 
such as cancer, we may gain a better understanding of regulation in normal cells and 
tissues.  
 
 
1.1.2     Hallmarks of Cancer 
 
 
It is now apparent that complex biological activity does not arise from specific 
individual molecules, but rather interactions among several components and involves 
different processes. Development of cancer is a multistep process resulting from the 
accumulation of failures or errors in the normal regulatory mechanisms initiated due to 
mutations of one or several genes in a cell. This altered cell then divides and multiplies 
along with normal cells. For survival, they eventually acquire additional aberrations 
including the ability to proliferate independently of normal environmental signals, 
gaining a growth advantage over its neighbouring normal cells, and allowing it to 
develop and form a malignant tumour. As the seminal review by Hanahan and Weinberg 
proposed the six hallmarks of cancer which has been a guide in the scientific community 
of cancer research since it was published 10 years ago, the following discussion was 
therefore adapted from this report. These six essential alterations of normal cell 
physiology that collectively results in cancer are: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (anti-growth) signals, evasion of apoptosis or 
programmed cell death, limitless replicative potential, sustained angiogenesis (blood 
vessel formation for nourishment), and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). A modified diagram is illustrated in Figure 1.A and will be outlined 
briefly in the following chapters. They represent the crucial processes in the 
transformation of normal cells to malignant cells via a process called clonal evolution 
which suggests that each time a genetic change occurs it confers a growth advantage to 
the cell to expand and out-compete other cells (Nowell, 1976; Merlo et al., 2006).  This 
genetic instability facilitates acquisition of other mutations as a result of defects in the 
normal DNA repair mechanism (Cahill et al., 1999).  The incidence of this instability 
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also rises dramatically with age, most likely due to a build up of risk factors from the 
individual’s genetic make-up, exposure to carcinogens and external agents such as 
chronic infections for specific cancers (e.g. HPV infection for cervical cancer), radiation, 
diet, tobacco and alcohol use (Jemal et al., 2010; Benz and Yau, 2008). 
 
Self-sufficiency in growth signals 
 
Normally, most soluble mitogenic growth factors are synthesized by specific cell types 
in order to signal other cells to divide and proliferate. Cancer cells however are able to 
produce many of their own growth signals, often termed autocrine stimulation, thereby 
eliminating the dependence on their normal tissue micro-environment, thus the hallmark 
“self-sufficiency in growth signals” (Hanahan and Weinberg, 2000). Moreover, this 
independence from the exogenous growth signals also changes the homeostatic micro-
environment, thereby instigating perturbations among surrounding normal tissues and 
cells. This acquired autonomy is usually caused by alteration of extracellular receptors 
(e.g. receptor tyrosine kinases), trans-cellular transducers of signals and intra-cellular 
circuits that translate growth signals into action (Robinson et al., 2000; Hunter, 2000). 
One of the most studied mutations that confer an oncogenic activity is the epidermal 
growth factor receptor (EGFR). EGFR is a member of the subclass I of the 
transmembrane receptor tyrosine kinase superfamily that plays a major role in the 
regulation of cell proliferation and other important processes for proper regulation of 
many developmental, metabolic, and physiological mechanisms of cells (Voldborg et al., 
1997; Waterman and Yarden, 2001; Holbro and Hynes, 2004). Binding of EGF or other 
growth factor ligands to the receptor causes homo- and hetero-dimers, subsequent 
autophosphorylation and activation of the kinase (Jiang and Hunter, 1999; Schlessinger, 
2000). This leads to stimulation of several complex intracellular signalling cascades, 
particularly RAS/RAF/ERK, a major signalling pathway of cell proliferation which will 
be discussed later in more detail. Mutations, amplifications or overexpression involving 
EGFR could lead to its constitutive activation, elicit ligand-independent activation or 
hyperresponsiveness to ambient growth factors, which can result in uncontrolled cell 
division (Honegger et al., 1990; Yarden and Sliwkowski, 2001). Consequently, 
deregulation of EGFR has been identified in several types of cancer, and it is the target 
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of an expanding class of anticancer therapies (Fan et al., 1993; El Sheikh et al., 2004; 
Green, 2004; Chinnaiyan et al., 2005)  
 
Insensitivity to growth inhibitory (anti-growth) signals 
 
In normal conditions, cells are maintained in a temporary non-dividing “quiescent” state 
by anti-growth signals, and then they resume proliferation upon appropriate signals. The 
most widely studied of the anti-growth factors is TGF (transforming growth factor-
beta) which upregulates the expression of cell cycle inhibitors such as the cyclin-
dependent kinase inhibitors p15, p21 and p27 (Hannon and Beach, 1994; Reynisdottir et 
al., 1995) and therefore has a crucial role in tissue homeostasis. However due to genetic 
instability, cancer cells have evolved to evade this signal, enabling the characteristic 
“insensitivity to growth inhibitory (anti-growth) signals”. Tumour cells evade normal 
TGFβ functions by selectively inhibiting its anti-proliferative response by 
downregulating TGFβ receptors and acquiring mutations in the TGFβ signalling 
pathway components (Parsons et al., 1995; Chen et al., 1998). Several studies have also 
demonstrated other mechanisms that are implicated in the disruption of TGFβ in 
promoting cell cycle arrest; such as mutations and deficiencies in retinoblastoma protein 
(pRb) and protein 53 (p53) which normally prevent replication of cells with damaged 
DNA, mutations in CDK (cyclin-dependent kinases), and perturbations in (mothers 
against decapentaplegic) SMADs (Tucker et al., 1984; Derynck et al., 2001; Heldin et 
al., 2009). Moreover in tumours, TGFβ not only loses its anti-growth function but can 
also induce proliferation, angiogenesis, invasion, metastasis and immune suppression (de 
Caestecker et al., 2000a; Shi and Massague, 2003; Seoane, 2006). 
 
Resistance to Apoptosis 
 
Cells are continually exposed not only to a variety of growth and anti-growth signals but 
experience stress and damage from exogenous and endogenous sources. Under this 
variety of circumstances, balancing physiological processes such as cell proliferation, 
development, differentiation and apoptosis are tightly controlled, which is essential to 
ensure normal growth and functions of organs, and tissue homeostasis of multicellular 
organisms (Hanahan and Weinberg, 2000). A major mechanism in this homeostatic 
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regulation is the process of apoptosis (Kerr et al., 1972). Programmed cell death or 
apoptosis is a normal regulatory process that cells promote in response to stresses such 
as nutrient or growth factor deprivation, heat, radiation, viral infection and other intra 
and extracellular signals that can trigger DNA damage or abnormalities that endanger 
the cells (Ameisen, 2002; Conradt, 2009). Apoptosis is characterized morphologically 
by contraction of cell mass, blebbing, loss of membrane asymmetry and attachment, 
nuclear fragmentation and formation of condensed cell bodies (Saraste and Pulkki, 
2000). Phagocytic cells consume these apoptotic bodies and its constituents are recycled 
(Kurosaka et al., 2003).  
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The underlying mechanisms of apoptotic cell death are highly regulated and complex. 
Briefly, apoptosis is an energy-dependent process that proceeds via two main pathways 
which are the extrinsic (death receptor) pathway and the intrinsic (mitochondrial) 
pathway. Induction of either pathway eventually leads to activation of caspases (cysteine 
aspartate proteases) that function as common death effector molecules by cleaving a 
range of cytoplasmic and nuclear substrates (Ellis et al., 1991; Elmore, 2007). The 
extrinsic pathway is activated by binding of a death ligand such as CD95L/FasL or TNF 
(tumour necrosis factor) –related apoptosis-inducing ligand (TRAIL) to their 
 
 
 
Figure 1.A. Outline of cellular processes affected by genetic alterations 
acquired in cancer cells. Illustration has been adapted from Hanahan and Weinberg, 
2000. Other emerging hallmarks of cancers or characteristics of cancer have been 
proposed, such as evasion of inflammatory surveillance, genomic instability and 
altered cell metabolism (reviewed by Hsu and Sabatini, 2008; Mantovani, 2009; 
Negrini et al, 2010).  
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corresponding death receptor which induces the formation of a death-signalling complex 
(DISC) (Locksley et al., 2001; Fulda and Debatin, 2006). This complex is capable of 
recruiting several procaspase-8 molecules through an adaptor molecule Fas-associated 
death domain (FADD), which results in cross activation of caspase-8 (initiator) and the 
release of active caspase-8 into the cytosol (Reed et al., 2004). Activated caspase-8 
initiates a caspase cascade by processing the (effector) caspases-3, 6, and 7 which in turn 
cleave a number of protein substrates (Cohen, 1997; Mandal et al., 2005). Alternatively, 
at low levels of caspase-8 the proapoptotic Bcl-2 family member BID (BH3-interacting 
domain) is cleaved, translocates to the mitochondria and causes release of apoptogenic 
factors such as cytochrome c to trigger the mitochondrial pathway (Cory and Adams, 
2002). The intrinsic or mitochondrial pathway can be triggered by toxic chemicals, DNA 
damaging agents, growth factor withdrawal, hypoxia, and ionizing irradiation (Herr and 
Debatin, 2001). Following cellular stress, the pro- and anti-apoptotic Bcl-2 family 
proteins interact in a complex fashion to mediate permeability of the mitochondrial outer 
membrane allowing the release of cytochrome c to the cytosol, triggering the 
commitment step of the mitochondrial apoptotic cascade (Igney and Krammer, 2002). 
Once released into the cytoplasm cytochrome-c binds to Apoptotic protease-activating 
factor 1 (Apaf-1), recruits procaspase-9 to create an “apoptosome”, a multi-protein 
complex that activates caspase-9 in the presence of ATP, which in turn activate caspase-
3 and caspase-7, leading to widespread activation of other caspases and the execution 
phase of apoptosis (Chinnaiyan, 1999; Hill et al., 2004). Cleavage of caspase substrates 
eventually leads to the characteristic morphological and biochemical features of 
apoptosis. It is therefore expected that one of the characteristic features of a cancer cell 
is the inability to undergo apoptosis in response to stimuli that would otherwise trigger 
apoptosis in sensitive cells, and to allow them to become more proliferative than normal. 
Cancer cells that harbour genetic alterations from important components of a normally 
functioning apoptosis machinery disrupts the ability of the cell to respond appropriately. 
Upon replication this faulty apoptotic mechanism is inherited by its progeny, increasing 
the capability to “evade programmed cell death” leading to the accumulation of aberrant 
cells (Hanahan and Weinberg, 2000). For instance, anti-apoptotic Bcl-2 proteins are 
over-expressed in a variety of tumours, and their expression is associated with resistance 
to chemotherapy (Sartorius and Krammer, 2002; Wesarg et al., 2007). The up-regulation 
of death receptors often occurs following chemotherapy and sensitizes tumour cells to 
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Fas ligand or other apoptotic-inducing ligands, rendering them less resistant to apoptosis 
(Dai and Grant, 2007). Thus, overexpression or underexpression of anti- and pro-
apoptotic gene products or mutations affecting key regulating genes of the apoptotic 
cascade may lead to evasion of, or resistance to, programmed cell death (Fulda and 
Debatin, 2006). However, it is important to note that other forms of programmed cell 
death such as autophagy and necrosis have been described, and are equally important 
and can also be exploited by cancer cells (Mizushima et al., 2008; Kroemer et al., 2009).  
 
Limitless replicative potential 
 
Most mammalian cells can only undergo a limited number of cell divisions due to 
progressive shortening of telomeres every cell cycle (Shay and Wright, 2002).  
Telomeres are a region of DNA which code for no proteins but are simply a repeated 
code on the end region of DNA strands. During the process of DNA replication, small 
segments of DNA at each telomere are unable to be copied and are lost after each time 
DNA is duplicated (Blackburn et al., 2006). It has been suggested that when the 
telomeres become too short, they unfold from their closed structure, and cells could 
detect this uncapping as DNA damage and therefore proceed to cellular senescence. This 
is also known as replicative senescence or the Hayflick phenomenon (in honour of 
Leonard Hayflick who first published this information in 1965), and may result in 
growth arrest, or even apoptosis, depending on the cell's genetic background, such as 
p53 or pRb integrity (Shay and Wright, 2000; Chen et al., 2006). This is a regulatory 
mechanism that allows a cell to prevent replicating errors that cause mutations in DNA. 
Telomeres are indeed essential in protecting the ends of chromosomes from degradation 
and preventing chromosomal end fusions and recombination (Masutomi et al., 2003). 
Aberrant cells that bypass this arrest become immortalized by telomere maintenance and 
extension due mostly to the activation of telomerase, the reverse transcriptase enzyme 
responsible for synthesis of telomeres (Blackburn et al., 2006). Many cancer cells are 
considered immortal because of high telomerase activity and are able to restore telomere 
length, conferring “limitless replicative potential” (Kelland, 2007). The high expression 
of telomerase in a wide range of human cancers is of major interest in cancer therapy, as 
it could be used as a diagnostic and prognostic biomarker (Gertler et al., 2008; Bisoffi et 
al., 2006).  
  25
Sustained Angiogenesis, Invasion and Metastasis 
 
In order for cells to function and survive they must be supplied with oxygen and 
nutrients. Cells must also be located within 100-200 μm of blood vessels, which is the 
diffusion limit of oxygen, for proper nourishment, survival and overall tissue 
homeostasis (Hanahan and Weinberg, 2000). It is therefore critical for the surrounding 
tissues to regulate and maintain a vascular network of blood supply for the delivery of 
adequate and important factors for growth and sustenance. Angiogenesis is a highly 
ordered process used by tissues in response to demands due to physiological or 
pathological conditions such as cancer or heart disease; it is the outgrowth of new 
capillaries or blood vessels from pre-existing vessels (Baluk et al., 2005). The 
development and formation of the normal vascular network is regulated by exchange 
equilibrium of anti- and pro-angiogenic factors. Deregulation of this process leads to 
underdeveloped or leaky vessels, and over growth or uncontrolled sprouting 
angiogenesis (Bergers and Benjamin, 2003).  
 
Cancer cells can therefore exploit this process to support their survival and growth by 
the process of “sustained angiogenesis", allowing tumours to progress to a larger size. 
This ability during tumour development is acquired via an initial “angiogenic switch”, 
an imbalance in the production of angiogenesis inducers and inhibitors (Hanahan and 
Folkman, 1996). Tumour angiogenesis is a multistep process which includes release of 
angiogenic factors such as vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factors (bFGF) which diffuse to surrounding tissues and bind to 
corresponding receptors (Baeriswyl and Christofori, 2009). Upon this initiation phase 
activated endothelial cells change shape; pericytes (mural cells of microvessels) detach 
from the blood vessel walls; degradation of extracellular matrix occurs (ECM) by the 
production of proteolytic enzymes; endothelial cells migrate and proliferate; and 
remodelling, stabilisation and maturation of new vessels occur (Bergfeld and DeClerck, 
2010) As tumours progress to increased malignancy, primary tumour cells eventually 
acquire the ability to undergo "invasion and metastasis" whereby cells invade into 
surrounding normal tissues and travel through tissue boundaries and distant sites in the 
body to form new colonies (metastases) at sites distinct from the primary tumour 
(Talmadge and Fidler, 2010).  
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1.1.3     Emerging Hallmarks of Cancer 
 
 
The steps that cells take toward becoming malignant cancers are variable, so that the 
order in which the hallmarks are acquired can vary from tumour to tumour and not all 
hallmarks have to be fulfilled for malignant cellular transformation to occur (Mantovani, 
2009). In fact, other emerging hallmarks of cancers or rather characteristics of cancer 
have been proposed such as evasion of inflammatory surveillance, genomic instability 
and altered cell metabolism and cancer stem cells (Hsu and Sabatini, 2008; Negrini et al, 
2010; Singh and Settleman, 2010). Even more recent is the observation of global 
reduction of microRNA (miRNA) levels in cancer (Esquela-Kerscher and Slack, 2006) 
particularly changes or alteration of gene expression is an emerging hallmark of cancer. 
MiRNAs are a class of short ribonucleic acid (RNA) molecules, on average only 22 
nucleotides long, noncoding RNAs that has been shown to regulate gene expression of 
cancer-related genes in various tissues, therefore they can be regarded to function as 
oncogenes or tumour suppressors, thus the link to tumourigenesis (Davalos and Esteller, 
2010). 
 
 
1.1.4     Genes involved in the onset of Cancer 
 
 
Induction and eventual deregulation of the normal cell processes that results in the above 
hallmarks of cancer are generated by two broad classes of genes; they are grouped into 
proto-oncogenes or tumour suppressors that play a crucial role in carcinogenesis as 
described below (Lee and Muller, 2010). These genes encode many kinds of proteins 
that regulate many key physiological processes such as cell cycle, growth, proliferation 
and apoptosis. Mutations that either increase the potential activation of proto-oncogenes 
or override the functional activity of tumour suppressors predispose cells to cancer 
development (Hanahan and Weinberg, 2000). Some tumour suppressor genes are 
classified as the stability or caretaker genes that maintain the integrity of the genome by 
ensuring fidelity of information transfer from one generation of cells to the next, and 
recognising or repairing DNA mismatch and damage (Levitt and Hickson, 2002). Their 
deregulation causes genetic instability that leads to a higher mutation rate of all genes 
including proto-oncogenes and tumour suppressor genes. However, no single mutation 
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gives rise to tumourigenesis, since mammalian cells have evolved a number of safeguard 
mechanisms to protect them from fatal effects of mutations that transform them into 
highly malignant cells but rather accumulation of mutations in these several types of 
genes will manifest the onset of cancer (Hanahan and Weinberg, 2011). 
 
Proto-oncogenes/ Oncogenes 
 
Proto-oncogenes are normal genes that encode proteins involved in different processes 
crucial for normal human cell development, growth and overall maintenance of tissues 
and organs. They become oncogenes due to mutations, often dominant because only one 
mutated allele is sufficient, that result in a constitutively activated protein product and 
leading to excessive and continuous cell proliferation (Lee and Muller, 2010). 
Conversion or activation of a proto-oncogene to an oncogene can be a consequence of 
gene duplication and chromosomal translocation that causes inappropriate ‘gain-of 
function’ expression of the encoded gene, which affects normal growth-regulatory 
processes such as  increasing cell cycle, loss of differentiation, inhibition of cell death 
and eventual induction of cancer (Cantley et al., 1991; Weinstein & Joe, 2006). 
Examples of proto-oncogenes include HER-2, Ras, Myc, Src, Bcr-Abl, Raf and ERK. A 
number of oncogenes that are important in the thesis will be described later. 
 
Tumour Suppressor genes 
 
Tumour suppressor genes (TSGs) regulate diverse cellular activities including cell cycle 
checkpoint responses, detection and repair of DNA damage, gene transcription, 
mitogenic cell signalling, differentiation and apoptosis (Simpson and Parsons, 2001; 
Sherr, 2004). Fundamentally, TSGs are growth regulating genes that inhibit or suppress 
inappropriate cell division and excessive proliferation. Importantly, these genes also 
promote apoptosis or cell death to maintain homeostasis of body tissues. Like proto-
oncogenes, tumour suppressor genes undergo a variety of mutations. ‘Loss-of-function’ 
or inactivation due to mutations and deletions of prototypic TSGs are usually recessive, 
that is it involves “two-hit” damage of both alleles of a gene to progress tumour 
formation (Knudson, 1971, 1973; Comings, 1973). For instance, retinoblastoma is a 
childhood form of retinal cancer that is caused by two mutations, one in each copy of the 
tumour suppressor gene now called RB1 (Friend et al., 1986). However, more and more 
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reports shows a number of TSGs do not conform to this classic model, such as 
haploinsufficient (single copy is not enough to confer normal function) genes requiring 
inactivation of only one allele (Santarosa and Ashworth, 2004), and silencing genes not 
by mutation but rather epigenetic hypermethylation (Ducasse, 2006). TSGs also appear 
to exhibit dominant negative (antagonise the wild-type allele) and gain-of-function (new 
and abnormal function) mutations which indicate a more complex view than originally 
thought (Payne and Kemp, 2005). This complexity is well exhibited by the p53 tumour 
suppressor gene (Menendez and Resnick, 2009). As it plays a crucial role in cell cycle 
regulation (growth arrest, DNA recognition, transcription of repair genes) (Marine et al., 
2006) and apoptosis (suppress replication of damaged DNA, induce cell death of 
damaged cells) (Zhang et al, 2007), loss of p53 function or inactivation abolishes 
apoptosis and allows abnormal cell division (genomic instability) (Rivlin et al., 2011), 
increased proliferation and increased susceptibility to carcinogenesis (Vousden and 
Prives, 2009). Hence, it is dubbed as the “guardian of the genome” (Lane, 1992; Efeyan 
and Serrano, 2007).  
 
 
1.1.5     Cell Signalling 
 
 
Oncogenes and mutated or inactivated tumour suppressor genes code for proteins that 
constantly interact in a dynamic fashion that includes a series of steps referred as the 
signal transduction cascade or cell signalling pathway. In normal cells, such cascades 
carry a signal from the cell membrane by receptor tyrosine kinases, usually activated by 
dimerisation (Heldin, 1995) and autophosphorylation of tyrosine sites (Hunter, 2000). In 
response, cytoplasmic effectors are activated and regulate internalisation of receptors or 
translocation of signals into the nucleus, to stimulate a regulated process such as cell 
growth (Pawson and Nash, 2000). Each step includes interaction of proteins such as 
recruitment of protein kinases by adaptors with specific activating domains that 
recognized by phosphorylated RTKs (Lowenstein et al., 1992), import or export of 
nuclear proteins and transcription factors to generate and process the signal (Chuderland 
et al., 2008). On the other hand, altered proteins encoded by mutated TSGs and 
oncogenes either disrupt this process or activate the signalling constitutively, for 
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example by over-production of growth factors which results in uncontrolled proliferation 
(Spivak-Kroizman et al., 1992). Cell signalling at the cellular level is complex, and 
involves many proteins and intermediary molecules including enzymatic activities 
(Metallo and Vander Heiden, 2010), movement of ions such as exit or entry of Ca+2 
through ion channels (Clapham, 2007), changes in protein conformation to induce 
interaction (Zhang et al., 2006), and gene expression such as induction or repression of 
transcription factors (Karin and Hunter, 1995). All cellular events such as cell survival 
and growth are a consequence of the dynamic interplay of these signalling cascades 
(Pawson and Nash, 2000). Multi-component cell signalling pathways also allow for 
feedback loops, signal amplification, and interactions between multiple signals and 
signalling pathways (Kolch, 2005). Some signalling transduction pathways process and 
respond differently, depending on the type and amount of signalling received by the cell 
(Hlavacek and Faeder, 2009). They respond to a multitude of stimuli from fluctuating 
environmental conditions which are required for homoeostasis to balance between life 
and death. In recent years, one of the most exciting new areas of study in the mitogen-
activated protein kinase (MAPK) signalling cascades has been the elucidation of 
putative scaffold proteins (Nishimoto and Nishida, 2006). Scaffold proteins regulate 
signal flux by coordinating protein complexes and distribute diverse signals to modulate 
and specify an appropriate response (Burack and Shaw, 2000). Their ability to facilitate 
such complex mechanisms is due to their intrinsic multidomain structure. Contributions 
to this research have further revealed a plethora of insights into our understanding, the 
complexity of intracellular signalling circuitry pathways and networks in mammalian 
cells (Dhanasekaran et al., 2007). 
 
 
 
1.2     Towards the study of CNK1 
 
 
1.2.1     The MAPK Pathway 
 
 
An evolutionary conserved signalling module, the mitogen-activated protein kinase 
(MAPK) pathway, is a key signalling pathway that when deregulated leads to 
development of cancer and other human diseases (Davies et al., 2002; Marais et at., 
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1998). Intensive research has been carried-out on the mechanisms of these pathways for 
a number of years in the hope of identifying and developing a drug for the treatment of 
cancer (Morrison et al., 2003; Reddy et al., 2003; Dhillon et al., 2007). A fundamental 
module downstream of a G-protein comprises a MAPK which is phosphorylated and 
activated by a dual specific MAPKK which is also phosphorylated and activated by a 
MAPKKK. Mitogens were the first group of stimuli shown to activate these pathways, 
hence the name given to this cascade of kinases (Ray and Sturgill 1987). A plethora of 
signals are now known to trigger specific response or crosstalk between pathways to 
elicit cellular events. A schematic overview in Figure 1.B depicts the complexity and 
organisation of MAP kinase cascades. 
 
 When MAP kinases are activated, a variety of membrane and cytoplasmic intracellular 
targets and nuclear substrates, including transcription factors, are phosphorylated or 
mechanistically interact with adaptor proteins and other protein kinases as well. There 
are currently nine distinct MAPK modules identified.  They are p38MAPKα/β/δ, Jun N-
terminal kinase (JNK) 1/2/3, extracellular signal-regulated (ERK) 1/2, ERK3/MAPK3, 
ERK4/MAPK4, ERK5/MAPK7, ERK6/p38MAPKγ, ERK7 and ERK8. In mammalian 
cells, six are well characterised to date. These are ERK1/2, ERK3/4, ERK5, ERK7/8, 
JNK1/2/3, p38 isoforms α/β/δ/γ41 (Dhanasekaran et al., 2007). The ERK1/2 or classical 
MAP kinases are serine/ threonine kinases that are ubiquitously expressed intracellular 
signalling molecules and are generally activated in response to growth factor-induced 
cell surface receptors (Boulton et al, 1991; Chang and Karin, 2001). The Jun N-terminal 
kinase (JNK) 1/2/3, also known as stress-activated protein kinases (SAPK), 
phosphorylate c-Jun on Ser63/Ser73 and p38 (Reddy et al., 2003). They are involved in 
apoptosis, inflammation and cell differentiation which are activated by stress stimuli 
such as cytokines, oxidation, UV radiation, heat and osmotic shock (Yoshioka, 2004). 
ERK5 has recently been shown to be activated both by stress and growth factors and 
translocates to the nucleus where it regulates gene expression by phosphorylating 
different transcription factors (Turjanski et al., 2007; Raman et al., 2007). As the MAPK 
pathways are involved in multiple cellular processes, deregulation in the control of the 
MAPK signalling pathways can lead to carcinogenesis. (Chang and Karin, 2001; Dhillon 
et al., 2007) 
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Figure 1.B. Schematic overview of the MAPK pathways. 
 
These pathways rely on signals that are processed through common mode of activation 
by phosphorylation of distinct motifs as shown below. However, the biological 
consequence varies widely. 
 
 
 
 
 
 
This schematic diagram is an oversimplification, and the actual roles of each MAPK 
cascade are highly complex, cell type and context dependent. Importantly, these 
pathways are activated by an enormous array of stimuli, and regulated by phosphatases, 
kinases and other enzymes including specialized proteins such as adaptors and scaffolds; 
they influence gene expression, cell cycle, metabolism, immune response and other 
critical biological processes as shown above. 
Legends: 
                             TEY, Thr-Glu-Tyr activation motif (ERK1, 2, 5, 7, 8) 
Phospho Motif     TPY, Thr-Pro-Tyr activation motif (JNK) 
                             SEG, Ser-Glu-Gly activation motif (ERK3, 4)  
                             TGY, Ser-Glu-Gly activation motif (ERK3, 4, p38) 
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1.2.2     The Ras/ Raf/ MEK/ ERK Pathway 
 
 
Among all the MAPK modules, the Ras-Raf-MEK-ERK (ERK/MAPK) pathway is one 
of the first described and best understood signal transduction pathways. It exemplifies 
how an extracellular stimulus is processed and transduced into the nucleus, which 
ultimately decides cell fate such as proliferation, differentiation and cell death. It is 
involved in about one third of all human cancers (Davies et al., 2002). This ERK/MAPK 
module consists of ERK (ERK1 and ERK2), which is activated upon phosphorylation by 
MEK (MEK1 and MEK2), which is activated upon phosphorylation by Raf (A-Raf, B-
Raf, Raf-1). The ERK/MAPK cascade signalling is initiated by binding of growth 
factors to (RTKs) Receptor Tyrosine Kinases (Hunter, 2000). This triggers guanosine-
triphosphate (GTP) loading of the Ras GTPase, which then binds and recruits Raf to the 
cell membrane for activation (Campbell et al., 1998). While at this time Raf and MEK 
appear to have only one substrate, ERK has been shown to have as many as 80 
substrates (Kolch, 2000). Early on, studies have shown that most cancer-associated 
aberrant activation of this pathway occurs at the level and upstream of Ras, including 
overexpression and mutations of RTKs and frequent mutation of Ras (Schlessinger, 
2000; Malumbres and Barbacid, 2003). Newer studies have shown that activation of this 
pathway in cancer can occur at different levels. More importantly, this increased 
expression of RTKs is associated with a poor prognosis (Repasky et al., 2004; Gollob et 
al., 2006). These cancer-causing aberrations of proteins are summarized in Figure 1.C. 
For instance, the recent discovery of B-Raf mutations in prevailing human cancers such 
as melanomas and colon cancer has proven that this module is far more complex than 
initially perceived (Wellbrock et al., 2004). Also, in the absence of clear genetic 
mutations, the ERK pathway has been reported to be hyperactivated in over 50% of 
acute myelogenous leukaemias and acute lymphocytic leukaemias (Garnet and Marais, 
2004; Chong et al., 2003; McCubrey et al., 2007) 
 
One of the most essential components of this pathway is the serine/threonine kinase, Raf 
(MAPKKK). The mechanism that regulates the small GTPase Ras as well as the 
downstream MEK and ERK is well understood, compared to the regulation of Raf itself 
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(Kolch, 2000). The Raf family consists of three isoforms; A-Raf, B-Raf and C-Raf (also 
known as Raf-1), all of which serve as immediate effectors of Ras and share MEK as a 
common substrate. They also share a common structure; each isoform contains three 
conserved regions; CR1, CR2 and CR3. The regulatory domain consists of the CR1 and 
CR2 which are located in the amino terminus. CR1 covers the RBD (Ras binding 
domain) and the CRD (Cysteine-rich domain). The kinase domain is at the C-terminus 
and comprises the CR3 region; however each demonstrates unique mechanisms of 
regulation and exhibits different physiological functions (Winkler et al., 1998; Okada et 
al., 1999; Kolch, 2000). For instance, activation by Ras of each isoform reveals common 
and different key individual phosphorylation sites which suggest that they can be 
regulated differently (Marais et al., 1997).  
 
 
Figure 1.C. Schematic overview of the Ras-Raf-MEK-ERK pathway and its 
cancer- associated lesions (modified from Wellbrock et al., 2004). 
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All three isoforms induce MEK/ERK activation, but differ in strength. MEK activity is 
highest when activated by B-Raf, followed by Raf-1 then A-Raf. Moreover, preferential 
activation of MEK species also exists among these isoforms. A-Raf has been shown to 
have preference to MEK-1 activation, while Raf-1 and B-Raf show no preference for 
either MEK-1 or MEK-2 in vitro (Wu et al., 1996). Knock-out mouse experiments show 
that A-Raf gene deletion resulted in neurological and gastrointestinal postnatal defects 
(Pritchard et al., 1996). Meanwhile, Raf-1 knock-out mice display a variety of 
abnormalities depending on the genetic background and mostly die during 
embryogenesis due to increased apoptosis (Huser et al., 2001; Mikula et al., 2001). 
Although MEFs from this mouse show no change of MEK/ERK activity, it was 
proposed that Raf-1 functions are compensated by B-Raf (Huser et al., 2001). Raf 
isoforms also vary in expression dependent on cell or tissue type. A-Raf emerged as the 
main isoform in urogenital cells while B-Raf is highly expressed in neuronal tissues, but 
at lower levels also in most other tissues. Raf-1 is ubiquitously expressed (O’Neill and 
Kolch, 2004). Collectively, these data suggest overlapping and distinct functions among 
individual isoforms. Since the main focus of this project is in association and at the level 
of Raf-1, it shall be discussed in more detail below. 
 
Although most studies have focused on Raf-1, the mechanism and function upon 
activation is still incompletely understood. Raf-1 activation is a complex multi-step 
process that involves dynamic changes in its phophorylation (serine, threonine and 
tyrosine residues), intermolecular dimerisation, protein-protein interactions and 
localisation as well as integration of other signalling pathways (Kolch, 2000; McCubrey 
et al., 2007). Accumulating evidence has demonstrated the significance of 
phosphorylation on different domains that control the regulation of Raf-1. For instance, 
Raf-1 in quiescent cells adopts an inactive conformation in the cytosol through the 
binding of 14-3-3 proteins to phosphorylated residues S259, and release from repression 
by 14-3-3 occurs upon Ras binding and displacement of 14-3-3 from pS259, which is 
subsequently dephosphorylated by PP1 or PP2A (Yip-Schneider et al., 2000; Ory et al., 
2003). This initiates further activation steps resulting in full activation of Raf-1. There 
are at least thirteen phosphorylation sites that are involved in the regulation of Raf-1 
(Dhillon and Kolch, 2002). They include S43 (targeted by PKA-Protein kinase A and 
ERK), S259 (targeted by AKT/Protein kinase B, PKA, PP2A-dephophorylation), S233 
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(phosphorylated by PKA), and S621 (PKA, AMPK) (Dhillon et al., 2002; Light et al., 
2002; Dumaz et al., 2003). Residues S43, S259 and S621 are constitutively 
phosphorylated (Dhillion et al, 2002). Raf-1 activation comprises the dephosphorylation 
of pS259 followed by phosphorylation of S338, Y340 and Y341 (Diaz et al., 1997; 
Chong et al., 2001). Phosphorylation at S338 can be mediated by p21 activated protein 
kinase (PAK1) (King et al., 1999), and reversed by protein phosphatase 5 (PP5) (von 
Kriegsheim et al., 2006). Src family kinases phosphorylate Y340 and Y341 (Fabian et 
al., 1993). S497 and S499 residues were identified as Protein kinase C (PKC) targets, but 
their role in activation is not entirely clear (Chong et al., 2003; Dhillon et al., 2007). 
Despite controversies over the details of Raf-1 activation through phosphorylation, it is 
clear that the regulation of Raf-1 reveals even more complexity to its mechanism.  
 
Protein: protein interactions also play a major role in the regulation of the 
Ras/Raf/MEK/ERK pathway. Interestingly, recent studies have shown that B-Raf 
interacts with and activates Raf-1. B-Raf/Raf-1 heterodimerization is part of the 
physiological activation mechanism that can be stimulated by mitogens, enhanced by 14-
3-3, and either isoform can activate the other (Rushworth et al., 2006). Raf-1 associated 
proteins described in the literature through biochemical and genetic approaches 
catalogue more than 35 proteins of different types and characteristics. These include 
chaperones (Hsp90/70), adapters/scaffolds (BAG-1, KSR, MP1, CNK1), phosphatases 
(PP2A, PP5), cytoskeleton and other kinds of proteins that are required for Raf-1 
activation (Kolch, 2000) or act as inhibitors (e.g. RKIP-Raf kinase inhibitor protein) 
(Yeung et al., 1999); and orchestrate localisation and assembly of multi-complexes for 
regulation of signals (Morrison and Davis, 2003; Shin et al., 2009). Notably, specialised 
proteins such as scaffolding proteins are now emerging as critical regulators of signal 
transduction pathways. Furthermore, as it will be discussed later, scaffold proteins play a 
major role in the processing, integration, duration and strength of signals and proper 
localisation of protein complexes (Kolch, 2005).  
 
Another intriguing feature of Raf-1 is that it has functions independent of MEK/ERK 
signalling. For instance, it has been shown that mitochondrially-targeted Raf-1 interacts 
with BCR-ABL to alter the phosphorylation of Bad in haematopoietic cells 
(Dhanasekaran et al., 2007). Raf-1 also interacts with the proapoptotic stress-activated 
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protein kinase ASK1 in vitro and in vivo thereby inhibiting apoptosis independent of its 
kinase function (Chen et al., 2001). ASK1 is a mediator of apoptosis induced by 
cytotoxic stresses including tumour necrosis factor (TNF), Fas and reactive oxygen 
species (ROS) (Hoeflich et al., 1999). Other non-catalytic functions include suppression 
of apoptosis in the membrane expression or clustering of Fas as well the regulation of 
Rho effector ROKα to stimulate cell migration (Yamaguchi et al., 2004). In addition, 
Raf-1 inhibits a novel proapoptotic pathway known as the MST2 signalling pathway, 
also independent of MEK activation (O’Neill et al., 2004). 
 
 
 
1.2.3     Raf-1 regulation of apoptosis  
 
 
The regulation of apoptosis is tightly controlled in parallel to cell growth and 
proliferation. Deregulation of this process can cause excessive and uncontrolled cell 
growth and proliferation, which is a common trait of cancer (Reddy et al., 2003). The 
classical Ras-Raf-MEK-ERK pathway has primarily been associated with cell 
proliferation. But now it is firmly established that this pathway is linked to several 
responses and it appears to have diverse roles such as the control of cell proliferation, 
differentiation and apoptosis (Wellbrock et al., 2004). As previously mentioned above, 
Raf-1 has been described to be involved in the inhibition of other pro-apoptotic proteins 
via direct binding and independent of its kinase activity. Moreover, deletion of Raf-1 in 
mouse models enhanced apoptosis while ablation of the proapoptotic kinase ASK1 could 
prevent this response (Yamaguchi et al., 2004; Ehrenreiter et al., 2005). In other knock-
out mice experiments, ablation of the Raf-1 gene also causes widespread apoptosis and 
embryonic lethality independent of MEK. But when a Raf-mutant (kinase-dead) that 
cannot be activated was knocked-back in, it resulted in viable mice, which suggests that 
Raf-1 kinase activity is not required for its suppression of apoptosis (Mikula et al., 
2001). In pursuit of this novel Raf-1 regulation of apoptosis, mammalian sterile 20-like 
kinase (MST2) was identified as an interacting partner of Raf-1 by a proteomic approach 
under serum starvation. It was demonstrated that Raf-1 binds to proapoptotic MST2 
kinase via the N-terminus of MST2. Conversely, B-Raf does not associate with MST1 or 
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MST2 and therefore has no direct involvement in the regulation on this pathway as Raf-
1 does (O’Neill and Kolch, 2004). The binding regions were mapped along the CR2 
region to amino acid sequence 151 to 301 that are unique to the Raf-1 isoform, which is 
consistent with the result that MST2 does not bind B-Raf. Sequential immunodepletion 
experiments also showed that Raf-1 under serum starvation recruits the entire pool of 
MST2. However, only a fraction of the total Raf-1 pool is bound to MST2 (O’Neill et 
al., 2004). Collectively, upon serum starvation Raf-1 binds to MST2, sequesters MST2 
monomers and prevents its dimerisation that is required for activation. In addition, Raf-1 
recruits a phosphatase (possibly PP2A) that dephosphorylates the activation loop 
phosphorylation site of MST2, thereby maintaining in its inactive state (O’Neill et al., 
2004). It was also shown that MST2 is constitutively active in Raf-/- cells and that its 
activity can further be enhanced by apoptotic stimulants such as Fas or Staurosporine. 
This suggested that the absence of Raf-1 leads to MST2 hyperactivation and eventual 
apoptosis. Moreover, kinase-dead and wild-type Raf-1 efficiently interacted with MST2, 
abrogating its phosphorylation and kinase activity, verifying that Raf-1 exerts a kinase 
independent prosurvival function (O’Neill et al., 2004). Studies on the regulation of 
pathways upstream of MST2 are emerging. Regulation of MST2 by Raf1 is not the only 
mechanism for control of this proapoptotic kinase. MST1 and MST2 have also been 
shown to interact with members of a tumour suppressor family known as Ras association 
family (RASSF) in the regulation of apoptosis (Matallanas et al., 2007). 
 
 
 
1.2.4     MST2 in a tumour suppressor pathway  
 
 
Mammalian sterile-20 (MST) kinases were first isolated as homologues of yeasts Ste20 
kinases. They consist of a catalytic domain in the N-terminal region, followed by a non-
catalytic region then an autoinhibitory segment and a coiled-coil domain that mediates 
dimerisation. MST1 (also known as Stk4 and Krs2) and MST2 (also known as Stk3 and 
Krs1) isoforms are very close homologues that are members of the class II germinal 
centre kinase (GCK) Ser/Thr kinases that promote apoptosis when overexpressed in 
mammalian cells (Creasy and Chernoff, 1995). Both homologues have been 
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demonstrated to be activated by stress and Fas signalling. They can activate the JNK 
stress response pathway either in a caspase-dependent or caspase-independent manner, 
and they may also translocate to the nucleus to phosphorylate histone H2B, resulting in 
DNA fragmentation (Jang et al., 2007; Radu and Chernoff, 2009). MST has also been 
described to inhibit the prosurvival AKT kinase. Conversely, MST1 is a substrate of 
AKT; it phosphorylates MST1 at S387 located at the C-terminal, blocking proapoptotic 
function and propensity for caspase activation (Guo et al., 2007). Recently, it was 
reported that in response to oxidative stress, MST1 can also induce apoptosis by 
phosphorylation and eventual activation of the transcription factor FOXO3a in neuronal 
cells (Lehtinen et al., 2006). The most widely known substrate of MST is the large 
tumour suppressor (LATS) kinase that belongs to the NDR/LATS subfamily of AGC 
(protein kinase A/PKG/PKC) which have been recently shown to regulate yes –
associated protein (YAP1/2), a proapoptotic transcriptional regulator (Hergovich and 
Hemmings, 2009). LATS kinase is a tumour suppressor gene originally isolated from 
Drosophila and has also been identified in mice and humans (Zhang et al., 2008).  In 
Drosophila LATS/Warts has been described as a central player in an emerging tumour 
suppressor pathway called the Hippo (MST 1/2 orthologue) pathway (Reddy and Irvine, 
2008). All known components of the Hippo signalling pathway are conserved in 
vertebrates.  
 
Mammalian homologues of Drosophila proteins in the Hippo pathway are as follows: 
FATJ for fat, NF2/Merlin for merlin, FRMD6 for expanded, RASSF1A for RASSF, 
MST1/2 for hippo, LATS1/2 for LATS/Warts, hWW45 for Sav/Salvador, MOB1A/B for 
MATS, and YAP for yorkie (Zhang et al., 2009). However, based on recent findings, not 
all mechanisms and connections seem to be conserved between Drosophila and 
vertebrates (Bao et al., 2011). It has been proposed that genes could have evolved and 
adapted to serve more complex requirements for signal transduction in mammals. 
However, discoveries made in Drosophila resulted in the elucidation of the core 
signalling mechanism of this MST/Hippo tumour suppressor pathway.  Consistent with 
this core module, a mammalian counterpart has been reported (Mattalanas et al., 2007). 
Figure 1.D depicts a mammalian model of this well conserved MST2/hippo-
LATS1/Warts-YAP1/Yorkie tumour suppressor pathway. It is noteworthy that unlike in 
Drosophila where upstream of hippo is Merlin and Expanded, upstream of MST2 is 
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RASSF1A and downstream Yorkie appears to be strictly anti-apoptotic while YAP1 
functions are more diversified in mammalian cells (Mattalanas et al., 2007; Dong et al., 
2007). 
 
 
Figure 1.D.  A Schematic overview of the MST2/Hippo signalling pathway 
through RASSF1A-induced apoptosis. 
 
RASSF1A-induced apoptosis through activation of Fas death receptor disrupts 
inhibitory Raf-1/MST2 complex by releasing MST2 and binding with RASSF1A. 
RASSF1A activates MST2 and promotes interaction with its substrate LATS1 
leading to phosphorylation of YAP1 by LATS1. Upon phosphorylation of YAP1 it 
dissociates from LATS1 and directs its translocation to the nucleus forming a 
complex with p73 which induces the transcription of the proapoptotic puma gene 
(Matallanas et al., 2007). 
 
 
MST kinases also associate with other members of the RASSF tumour suppressor family 
through a leucine zipper-like motif known as SARAH (Sav-RASSF-Hpo) protein-
protein interaction domain including the aforementioned RASSF1A (Hwang et al., 
2007). There are 8 members of the RASSF family of proteins, which are RASSF1-8. 
RASSF1-6 contains a Ras domain (RA) of the Ral-GDS/AF6 type apart from the 
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SARAH domain at the C-terminus. Small GTPases such as Ras and Rap have been 
shown to interact with RA domains of the RASSF family of proteins (van der Weyden 
and Adams, 2007). Studies suggest that a number of Ras signalling molecules in 
association with additional apoptotic pathway protein complexes may play a role in 
proapoptotic MST signalling through RASSF tumour suppressors (Agathanggelou et al., 
2005). RASSF1A and RASSF5 (also known as Nore1a, novel Ras effector 1) have been 
described to activate MST kinases by mutant Ras and Fas, respectively (Vos et al., 
2000). RASSF1A is made of 340 amino acids and contains a cysteine-rich domain 
(CRD) similar to that of the CRD domain of Raf-1 which is absent in RASSF1C 
isoform. Both isoforms have been subjected to extensive studies, in contrast to other 
RASSF family members. RASSF1A is one of the most frequently silenced genes in a 
wide variety of human cancers (Sherwood et al., 2010). A number of studies have 
demonstrated that overexpression of RASSF1A induces apoptosis or cell cycle arrest 
(Song et al., 2005). In addition, it decreases tumourigenicity of several cancer cell lines 
(van der Weyden and Adams, 2007). Knockdown experiments by RNAi results in 
genetic instability and loss of cell cycle control including resistance to K-Ras and TNFα 
(tumour necrosis factor α) induced-apoptosis (Guo et al., 2007). It has also been 
observed that RASSF1A can regulate BAX (Bcl2-associated X protein) activity through 
binding to MOAP1 (modulator of apoptosis 1). BAX, a MOAP1 binding protein is a 
member of the Bcl2 (B cell CLL/ lymphoma 2) family that plays a major role in 
protecting against apoptosis (Baksh et al., 2005). Thus, RASSF1A has the ability to bind 
and coordinate multiple pathways (Richter et al., 2009). Intriguingly, RASSF1A lacks 
enzymatic activity, but has multiple binding partners, suggesting that it might function as 
a scaffold protein. 
 
 
 
1.2.5     Connector enhancer of KSR (CNK) 
 
 
Interestingly, a scaffold protein known as CNK1 which has been described to activate 
Raf-1 through Src appears to be involved in the activation of MST kinases by RASSF1A 
and Ras (Ziogas et al., 2004). The interaction of RASSF and MST SARAH domains are 
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under the negative regulation of Raf-1 (Matallanas et al., 2007). But the exact 
mechanism of this interaction is still unclear. As depicted in Figure 1.E, given the role of 
CNK as a scaffold protein, it may possibly facilitate high local concentrations of RASSF 
and MST to enhance SARAH domain interactions. Another possible role of CNK is to 
exclude the negative signal of Raf-1, or it may facilitate Ras regulation of the Raf-MST 
complex. Fas stimulation also activates MST by removal of an inhibitory Raf-1 
interaction (O’Neill et al., 2004). It is therefore of great interest to examine the 
mediation of CNK1 in reference to opposing physiological stimuli. How receptor 
signalling transmits signals to activate the MST signalling pathway either via 
localisation or protein interaction is still less understood. A proposed mechanism could 
involve compartmentalisation of effectors and adaptors to regulate such protein 
complexes, as it appears to be a common theme among established signalling pathways 
such as the ERK/MAPK pathway. For instance, the relationship of cell proliferation and 
apoptosis is immensely complex. Accumulating evidence details that nature has 
developed a mechanism to finely tune this regulation and this mechanism has been 
attributed to a specialised type of proteins that contain a multidomain structure and 
which are classified as scaffold proteins (Levchenko et al., 2000; Bhattacharyya et al., 
2006).  
 
The scaffold protein Connector enhancer of Kinase suppressor of Ras (CNK) was 
discovered in a genetic screen in Drosophila as an enhancer of the dominant negative 
rough-eye phenotype, which occurs due to the inhibition of photoreceptor development 
caused by a mutation in KSR (Therrien et al., 1998). CNK has no apparent catalytic 
motifs, however it has several protein: protein interaction domains. Four domains that 
indicate possible interaction sites with other proteins were identified. They comprise a 
sterile alpha motif domain (SAM) located at the N-terminus; a CRIC domain, a PSD-
95/DLG-1/ZO-1 (PDZ) domain; and the pleckstrin homology (PH) domain in the middle 
of the protein. Although only a few SAM domain containing proteins have been 
characterised, they are found in a wide variety of proteins. SAM domains have distinct 
functions; they can homo or hetero-oligomerize, bind to RNAs, or associate with 
membrane lipids (Qiao and Bowie, 2005). The SAM domain of Drosophila CNK has 
been functionally studied. It was found to be essential for viability as well as Ras-
mediated ERK activation through a novel protein called HYP (Hyphen)/AVE (Aveugle), 
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a step upstream of D-Raf and downstream of Ras. It was shown that the SAM domain on 
CNK and the SAM domain of HYP heterodimerise, recruit KSR (kinase suppressor of 
Ras)/MEK complex and activate D-Raf (Douziech et al, 2006). PDZ domains are also a 
prevalent class of domains that are often involved in scaffolding signal transduction 
complexes and localising proteins to the cytoskeleton, mostly through their ability to 
recognise and bind to short polypeptide motifs (X-S/T-X,-hydrophobic X, X-
hydrophobic X-X-hydrophobic X, X-D/E-X-hydrophobic X) at the C-terminal of the 
target proteins (Sheng and Sala, 2001; Appleton et al., 2006). 
 
Figure 1.E.  A proposed model where CNK1 may well be situated in the 
RASSF1A/MST2/Raf-1 signalling pathway. 
 
 
Growth factor stimulation restricts the binding of Raf-1 to MST2, while Fas receptor 
stimulation activates MST2 by removal of inhibitory Raf-1 in the presence of RASSF1A 
(Mattalanas et al., 2007). Exactly how this task is achieved is not clear. To add to this 
complexity, the mechanism parallel to Raf-1 or upstream of this signalling cascade is not 
well understood. Previously identified as an interacting protein of each of these proteins, 
the scaffold protein CNK1 may play a crucial role in the coordination of MST2 binding 
to the inhibitory Raf-1 or activating RASSF1A protein complexes. 
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PH domains, like PDZ, domains generally function as regulated binding modules 
(approximately 100-130 amino acids) that are involved with many regulatory pathways 
(Lemmon, 2004). A diverse array of proteins contains PH domains. These include 
serine/ threonine kinases (such as AKT), phopholipase Cs, GTPases, adapter/scaffold 
proteins, cytoskeletal proteins and kinase substrates (Blomberg et al., 1999). 
 
The PH domain of hCNK1 (human CNK1) has been found to interact specifically with 
the GTP-bound form of Rho (Jaffe et al., 2004). Human CNK1 overexpression of a 
mutant containing a single amino acid substitution (CNK W493A) in the PH domain (aa 
404 to 504) abolishes Rho binding and inhibits Rho-dependent transcriptional activation. 
In addition to these three domains, a conserved region in CNK (CRIC) is described as 
another binding interface.  The hCNK1 CRIC domain has been shown to associate with 
AT2 (Angiotensin 2) receptor, MLK 2/3 (mixed-lineage kinase) and Rhophilin (Fritz 
and Radziwill, 2005; Jaffe et al., 2004). The conserved region among chordate (CRAC) 
is found only in vertebrates and it has also been described as a binding site that is 
required for the interaction of IPCEF1 (Interaction protein for cytohesin exchange 
factors 1) with the coiled-coil motif of Cytohesin-2 (Venkateswarlu, 2003). The Raf 
inhibitory region (RIR) only exists in Drosophila (Therrien et al., 1998). The Drosophila 
CNK protein has a unique mechanism of Raf-1 regulation not found in mammalian CNK 
proteins. In Drosophila, CNK (1557 amino acids) mediates Ras activation of D-Raf 
through their SAM and CRIC domains, but inhibits D-Raf through the RIR motif in the 
C-terminus. In addition, binding of SRC42 (Drosophila homologue of mammalian Src) 
to CNK relieves D-Raf from repression by RIR, enhancing D-Raf activity (Douziech et 
al., 2003).  
 
This bimodal mechanism again is consistent with a typical scaffold property, which is 
integration of two opposing functions. CNK proteins also contain short motifs such as 
proline-rich and tyrosine residues that are within binding sites for consensus SH3 (Src 
homology 3) and SH2 (Src homology 2) domains respectively (Kolch, 2005). A 
schematic diagram of the multidomain structure of Drosophila CNK compared to 
mammalian CNK is shown in Figure 1.Fa and 1.Fb respectively. This structural 
organization indeed suggests CNK as a putative scaffold protein, and predicts an ability 
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to interact with several proteins and assemble various proteins into unique complexes to 
promote specific signalling responses. In contrast to Drosophila and Caenorhabditis 
elegans, mammalian CNK has three isoforms (Therrien, 1998). Namely; CNK1 which is 
widely expressed, CNK2 found mainly in neurons is also known as MAGUIN1  
(membrane-associated guanylate kinase-interacting protein 1) that has shown to 
associate with Raf signalling complexes but independent of the ERK/MAPK pathway 
(Yao et al., 1999; Yao et al., 2000), and CNK3, which has yet to be functionally 
characterised. 
 
Figure 1.F.  A schematic diagram of the multidomain scaffold protein CNK in (a) 
Drosophila and (b) mammals (modified from Kolch, 2005).  
 
 
 
Two variants have been identified for CNK3, namely CNK3A and CNK3B. CNK3B, 
also known as PIP-3E (Phosphoinositide- binding protein 3E), was identified to 
associate with IPCEF1 in a yeast two-hybrid screen (Krugmann et al., 2002). CNK2 
appears to be the closest homologue of CNK found in fly and worm that encodes two 
isoforms with distinct C-termini. They are referred to as CNK2A and CNK2B. Unlike 
CNK2B, CNK2A ends with a PDZ binding motif (ETHV) that is necessary for 
interacting with Densin-180, PSD-95 and S-SCAM which suggests a role for the 
  45
assembly of a postsynaptic protein complex (Ohtakara et al., 2002). CNK2 also 
associates with Raf-1 and B-Raf isoforms. However, the mechanism of CNK2/ B-Raf 
interaction is not well understood. Also, CNK2 binds to Raf-1 but is unable to 
precipitate Ras, MEK, ERK or KSR which suggests that its function may not be 
restricted to the ERK/MAPK pathway, or that it could assemble components that do not 
interact with ERK/MAPK complexes (Lanigan et al., 2003). In addition, studies done on 
PC12 cells showed that CNK2 is required for ERK/MAPK activation by NGF (nerve 
growth factor) as well as neurite outgrowth, in contrast to EGF (epidermal growth factor 
(Bumeister et al., 2004).) However, the authors also showed that CNK2 might be also 
involved with actin remodelling by binding to a tumour suppressor protein, DAL-1/band 
4.1b (differentially expressed in adenocarcinoma of the lung 1) but was independent of 
ERK/MAPK. DAL-1 is a member of the band 4.1 family of proteins implicated in 
regulation of cytoskeleton and plasma membrane organization (Tran et al., 1999). 
Therefore, CNK2 may be involved with Raf-1 in ERK/MAPK-dependent and 
ERK/MAPK-independent manner. CNK2 was also found to associate with RAL (Ras-
like protein) GTPase and RLF (RalGDS-like factor) which is a member of the RALGDS 
(Ral guanine nucleotide dissociation stimulator) family of GEF (guanosine exchange 
factor) that activate RAL (Lanigan et al., 2003). However, CNK2 overexpression did not 
significantly activate RAL or cause RLF membrane localisation. 
 
 Although few studies have now addressed the role of CNK in mammalian cells, the 
most studied of all mammalian CNK isoforms is CNK1. Mammalian CNK1 binds Raf-1 
and Src concurrently, which results in a trimeric complex that enhances Raf-1 activity 
and promotes phosphorylation at Y341, a Raf-1 activation site (Ziogas et al., 2005). It 
was demonstrated that CNK1 modulates the Src-dependent activation of Raf-1 in a 
concentration dependent manner typical of a scaffold protein. In addition, siRNA 
depletion of endogenous CNK1 interfered with Src-dependent VEGF (vascular 
endothelial growth factor) activation of ERK Clearly, CNK1 and CNK2 isoforms are 
implicated in RTK (receptor tyrosine kinase) induced Ras/ERK signalling indirectly or 
directly in association with Raf-1.  In C. elegans, it was shown that CNK1 is not an 
essential component of Ras signalling, but could promote Raf activation as an accessory 
protein (Rocheleau et al., 2005). The group showed through genetic studies that CNK1 is 
downstream of Ras at a step leading to LIN-45 (abnormal cell LINeage-45; C. elegans 
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Raf-1 homologue) activation, consistent with data from Drosophila. Also, by using 
various activated forms of LIN-45, it was shown that CNK1 promotes activation of LIN-
45/Raf-1 after dephosphorylation of the inhibitory sites and before phosphorylation in 
the kinase domain. Therefore, these data suggest a model in which CNK1 may promote 
Raf-1 membrane localisation, oligomerization or interaction with an activating kinase. 
Moreover, CNKs may have additional functions and phenotypes that have not yet been 
observed in model organisms dependent or independent of Ras/ERK signalling. For 
instance, human CNK1 has been identified as an effector of the Rho GTPase (Jaffe et al., 
2004). Rho family GTPases act as molecular switches that regulate cellular responses 
such as cell transformation, cytoskeleton rearrangement and gene expression (Ellenbroek 
and Collard, 2007).  Rho proteins cycle between an inactive GDP-bound and an active 
GTP-bound form. GTP loading is mediated by guanosine nucleotide exchange factors 
(GEFs).  CNK1 was shown to interact with two Rho-specific GEFs (Net1, 
p115RhoGEF) and assemble components of JNK (c-Jun N-terminal kinases) signalling 
pathway that includes MKK7, MLK2 and MLK3 to activate JNK in a Rho-dependent 
manner (Jaffe et al., 2005). It was also found to associate with Rhophilin a Rho effector 
protein and RalGDS (Ral guanine nucleotide dissociation stimulator) Ral associated 
proteins are involved in membrane trafficking, transcriptional regulation and cell 
transformation (Jaffe et al., 2004). Although these interactions have been observed, the 
functional correlation remains to be elucidated. 
 
 Another CNK1 interacting protein, AT2 (Angiotensin II Type 2) receptor, has been 
found, but again no function has been demonstrated. AT2 receptor is a G protein-
coupled receptor that antagonizes receptor tyrosine kinases to inhibit cell proliferation or 
promote neuronal differentiation and apoptosis (Fritz and Radziwill, 2005). Intriguingly, 
one of the most recent additions to this various array of CNK binding partners is 
RASSF1A. As mentioned above, RASSF1A is a tumour suppressor that is implicated in 
cell cycle arrest and apoptosis, which has been found to interact with CNK1 through 
MST1/2 (Rabizadeh et al., 2004). It was observed that CNK1 contributes to Ras-
mediated apoptosis by its ability to bind RASSF1A and the proapoptotic kinases 
MST1/2. Thus, apart from Src-mediated activation of Raf-1, mammalian CNK is also 
involved in other signalling pathways by interacting with a variety of proteins which 
includes; RalGDS (Ral guanine nucleotide dissociation stimulator), RLF (RalGDS-like 
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factor), Rhophilin and DAL-1/band 4.1b, a tumour suppressor which regulates the actin 
cytoskeleton, Rho-dependent JNK pathway, RASSF1A (Ras-association domain family 
1) and MST2, which regulates apoptosis. Mammalian CNK therefore regulates at least 
four signalling pathways. Recently, it was demonstrated that CNK1 is also involved in 
PI3K/AKT (Lim et al., 2010), NFκB (Fritz and Radziwill, 2010) and AKT/FOXO 
signalling (Fritz et al., 2010). All together these findings suggest that CNK1 could 
mediate crosstalk between signalling pathways, indeed establishes CNK1 as a true 
scaffold protein. However, much has yet to be learned about its mode of action, 
including its functional interdependency. Hence, to determine whether the pathways are 
regulated independently and, if linked, whether they cross-talk in a combinatorial 
manner, will be an enormous endeavour. A proposed approach to tackle this challenge 
that will dramatically improve our ability to understand this molecular complexity is the 
application of mathematical computer modelling that enables a system-wide analysis of 
intertwined signalling networks (Heinrich et al., 2002; Orton et al., 2005; Kolch et al., 
2005). More intriguingly, recent studies have also proven that exploiting experimentally 
the domain-based modular structures of scaffold proteins to generate synthetic signalling 
pathways, artificial control mechanisms and re-wiring gene expression is essential in 
elucidating the regulation of signalling pathways (Pryciak, 2009). Alternatively, it may 
translate to possible new directions for the future development of compounds or 
complexes to targeted-cancer therapy (Bhattacharyya et al., 2006; Pawson and Warner, 
2007).  
 
 
 
1.2.6     Perspective on scaffold proteins  
 
 
Over the past several years, studies in signal transduction have revealed that intra- and 
extracellular signalling involves assembly of multiple protein complexes, specific 
localisation of proteins and dynamic regulation of kinases and phosphatases to carry-out 
intricate tasks within the cell (Morrison and Davis, 2003; Yoshioka, 2004). The 
mechanism of achieving this multifaceted function has been attributed to scaffold 
proteins. The localisation and compartmentalisation roles of scaffold proteins are now 
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widely accepted in cellular signalling, which has been demonstrated in the literature 
(Dhanasekaran et al., 2007). The concept and potential function of scaffolding proteins 
was postulated more than a decade ago through computational modelling. These 
theoretical simulations have been very helpful in understanding at least some of the 
many complex functions of scaffold proteins (Kolch, 2005). These proposed principles 
that govern scaffolding properties also provided conceptual guidelines in experimental 
work (Burack and Shaw, 2000). A typical signature of a scaffold protein is the 
manifestation of a non-monotonic behaviour (bell-shaped) of a signal output as a 
function of scaffold concentration in a titration curve. This phenomenon is often referred 
to as ‘prozone-effect’ or combinatorial inhibition (Ferrell, 2000). A schematic diagram 
of this behaviour is shown in figure 1.G. As depicted in the diagram, the relative 
stoichiometry of a scaffold to its client proteins can have an opposing effect on the 
signalling module. At low levels of scaffold as compared to its client proteins the 
binding of kinases to their substrate is inefficient, so signalling is below the optimum 
activation. When kinases and substrates are bound to scaffolds at an optimum 
stoichiometric level, they are tethered in nearest neighbour positions. 
 
Figure 1.G.  Combinatorial inhibition of kinase activity by scaffold proteins. 
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Moreover, scaffold protein can also orient and allosterically activate kinases; therefore 
signal enhancement is achieved (Pawson and Nash, 2003). However when the scaffold 
level is in excess in comparison to the kinases and substrates, non-functional kinase-
scaffold/substrate-scaffold complexes are formed. Thus, signalling is impaired. At this 
high level of scaffold, it becomes an inhibitor of the signalling complex. A good 
example of this phenomenon has been demonstrated with the scaffold protein JIP-1 
(JNK-interacting protein 1). In the JNK (c-Jun N-terminal kinase) cascade; MKK7, 
DLK, MLK3 and JNK associate with JIP-1.  JIP-1 can enhance JNK activation but when 
overexpressed, it acts as an inhibitor (Whitmarsh et al., 2001). In the ERK/MAPK 
pathway, KSR-1 (kinase suppressor of Ras 1) scaffold protein also exhibits this 
behaviour. At an optimum level, KSR interacts with Raf-1, MEK and ERK. However, at 
the endogenous level, Raf-1 is difficult to immunoprecipate with KSR. At a higher level 
of KSR, ERK activity is inhibited. Moreover, in KSR-1 null fibroblasts ERK activation 
is severely compromised (Kortum and Lewis, 2004). Analogous observations have been 
made with other scaffold proteins such as IQGAP1 (Roy et al., 2005) and MORG1 
(Vomastek et al., 2004). Mathematical models also predict that scaffold-mediated 
protein complexes can effectively modulate signal efficiency and specificity as well as 
the amplitude (Ferrel, 2000; Locasale et al., 2007). Indeed, recent evidence has validated 
some of these theoretical predictions of scaffold-mediated signal transduction.  Although 
a number of studies have shown that scaffold proteins play an essential role in 
facilitating signal transduction, the specific mechanistic induction of dynamic scaffold-
formation complex and disassembly is poorly understood. Moreover, there seem to be 
more questions arising from this ostensible mechanism that scaffold proteins exhibit, 
either through theoretical simulations or experimental approaches. 
 
 
1.2.7     Aims of PhD  
 
The overall objective of this thesis was to investigate a possible role of CNK1 in the 
regulation of MST2 and Raf-1. To determine whether CNK1 manifests a concentration-
dependent property that is typical of a scaffold protein and to examine its role in 
mediating the agonist functions of proto-oncogene Raf-1 and tumour-suppressor MST2. 
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Materials and Methods 
 
 
2.1     Materials 
 
 
2.1.1 Antibodies 
 
 
All anti-serum was used at 1:1000 unless stated otherwise here. 
 
 
BD Transduction Laboratories  
 
Anti-hCNK1 (1:500) (Mouse, Catalog number: 611734) 
Anti-c-Raf-1 (Mouse, Catalog number: 610152)  
Anti-PARP (Mouse, Catalog number: 556362) 
 
 
Cell Signalling 
 
Anti-P-Threonine (Rabbit, Catalog number: 9381) 
Anti-phospho-MEK1/2 (Rabbit, Catalog number: 9121) 
Anti-MEK1/2 (Rabbit, Catalog number: 9122) 
Anti-Phopho-Raf S259 (Rabbit, Catalog number: 9421) 
Anti-Rabbit IgG (HRP) (Goat, Catalog number: 7074) 
 
 
Epitomics 
 
Anti-MST2 (N-term) (Rabbit, Catalog number: 1943-1) 
Anti-pMST2 (pT183/pT180) (Rabbit, Catalog number: 2111-1) 
 
 
MBL 
Anti-Fas/CD95 (Mouse, Catalog number: SY-001) 
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Santa Cruz Biotechnologies 
 
Anti-MST2 (C-19) (Goat, Catalog number: SC-6211) 
Anti-Tubulin (1:2000) (Mouse, Catalog number: SC-8035) 
Anti-LATS1 (G-16) (Goat, Catalog number: SC-12494) 
Anti-Mouse IgG (HRP) (Goat, Catalog number: SC-2060) 
Anti-Goat IgG (HRP) (Donkey, Catalog number: SC-2020) 
 
 
Sigma  
 
Anti-phospho-ERK1/2 (1:20000) (Rabbit, Catalog number: M5670) 
 
 
Upstate 
 
Anti-Myc (Mouse, Catalog number: 05-724) 
 
 
 
 
2.1.2 Primers 
 
 
Beatson Institute Sequencing Service 
 
CMV-F (5’ CGC AAA TGG GCG GTA GGC GTG 3’) 
T7- (5’ TAA TAC GAC TCA CTA TAG GG 3’) 
 
 
Site-directed mutagenesis 
 
CNK1 S377A 
Forward (5’-3’) TTG GTC GGA AGA AAG CAA AAG GCC TGG CGA CC 
Reverse (5’-3’) GGT CGC CAG GCC TTT TGC TTT CTT CCG ACC AA 
 
CNK1 S377D 
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Forward (5’-3’) AAG AGT CCT GTT GGT CGG AAG AAA GAT AAA GGC CTG 
GCG ACC 
Reverse (5’-3’) GGT CGC CAG GCC TTT ATC TTT CTT CCG ACC AAC AGG ACT 
CTT 
 
 
2.1.3 RNAi 
 
 
Dharmacon 
 
5X siRNA buffer  
 
Non-targeting control (NTC; D-001810-01) 
 
Human CNK1 (SMARTpool M-012217-01-0010) 
 
Human MST2 (J-J 004874-07) 
 
Human Raf-1 (M-003601-00) 
 
Human RASSF1A (J-017219-05-0010) 
 
 
 
2.1.4 General Reagents and consumables 
 
 
All reagents were purchased from Sigma-Aldrich unless stated otherwise here. 
 
Amersham Biosciences  
[35S] methionine 
PVDF membrane 
 
Becton Dickinson  
Insulin-like Growth Factor 
15 ml conical tubes 
50 ml conical tubes 
Falcon 2054 tubes 
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Transfer pipettes 
Tissue Culture plates 
Tissue Culture flasks 
 
Biorad  
Western blot modules 
Semi-dry transfer module 
Precision Plus Protein Standards (Dual Color) 
β-mercaptoethanol 
 
Calbiochem 
Nonidet P-40 
 
Costar 
6-well tissue culture plates 
 
Fisher Scientific 
Ethanol 
Methanol 
Glycine 
Glycerol 
KCl, MgCl2, CaCl2 
MgSO4, NaCl 
SDS 
 
Fuji  
RX medical X-Ray Film 
 
Gibco  
Dulbecco’s modified eagle medium 
EDTA/ Trypsin 
L-Glutamine 
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Hyclone  
Foetal Bovine Serum 
 
Invitrogen  
Lipofectamine 2000 reagent 
TOP10 Oneshot competent cells 
Novex XCell SureLock Mini-Cell Module system 
NuPAGE® 4-12% Bis-Tris Gels 
NuPAGE® Running Buffer 
NuPAGE® Transfer Buffer 
 
Kodak 
Ammonium Persulfate 
Kodak medical X-Ray film 
 
Melford Laboratories 
Tris Base 
 
Molecular Probes  
Propidium Iodide 
 
New England Biolabs 
Calf Intestine alkaline phosphatase 
 
Promega  
Caspase 3/7-Glo Assay Kit 
TNT Quick Coupled Transcription/Translation Systems Kit 
 
Promocell 
Cryo-Serum Free Media 
 
Promokine 
Epidermal Growth Factor 
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Qiagen 
RNAseA 
Restriction enzymes, BamH1 and Ecor1 
QIAprep Miniprep Kit 
QIAGEN Plasmid Maxi Kit 
QIAEX II Agarose Gel Extraction Kit  
 
R&D Systems 
Human TGF-ß1 
 
Roche  
DNA Ligation Kit 
Western Blocking Buffer 
Complete Protease Inhibitor cocktail tablet 
PhosSTOP Phosphatase Inhibitor cocktail tablet 
BM Chemiluminescence substrate POD 
 
Severn Biotech Ltd. 
30% Acrylamide 
 
Stratagene  
QuickChange II Site-Directed Mutagenesis Kit 
XL Blue competent cells 
 
Thermoscientific 
Microplate 96 well optical flat bottom plate 
Cryo Freezing microtubes 
Tissue culture flasks 
 
Whatman 
3MM Chromatography paper 
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2.1.5 General Solutions/Buffers 
 
 
PBS 
137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.47 mM KH2PO4 
(Adjust to pH 7.4 if necessary with HCl or NaOH) 
 
 
TBST 
137 mM NaCl 
20 mM Tris base 
0.1 % (v/v) Tween-20 
(Adjust to pH 7.6 with concentrated HCl) 
 
 
LB-medium 
1.0 % Bacto-Tryptone 
0.5 % Bacto-yeast extract 
1.0 % NaCl 
(Adjust pH to 7.5 with 5M NaOH if necessary, Autoclaved) 
 
 
TE buffer 
1mM EDTA  
10 mM Tris-HCl pH 7.4 
 
 
PBT 
0.5%BSA 
0.1% Tween-20 
PBS buffer pH 7.4 
 
 
NuPAGE MOPS running buffer 
50 mM MOPS 
50mM Tris base 
0.1% SDS 
1 mM EDTA 
(pH 7.7) 
 
 
NuPAGE transfer buffer 
25 mM Bicine 
25 mM Bis-tris (free base) 
1 mM EDTA 
(pH 7.2) 
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Methods 
 
 
2.2     Cell Culture 
 
 
2.2.1 Growth conditions 
 
HeLa cells and MCF-7 cells were maintained in Dulbecco’s modified eagle medium 
(DMEM, Gibco) supplemented with 10% (v/v) Foetal Bovine Serum (Hyclone) and 
2mM L-Glutamine (Invitrogen/ Life Technologies). Cells were grown in a humidified 
atmosphere containing 5% CO2 at 37ºC. Cells were passaged when sub confluent 
(~80%) using buffered trypsin (0.05% trypsin, 0.02% EDTA, obtained from Gibco) and 
diluted with fresh media at a ratio of 1:3. Cell culture was performed using aseptic 
technique and sterile equipment and reagents in a class II hood. 
 
2.2.2 Cell storage 
 
Cells were stored by cryo-freezing. Trypsinised cells were resuspended in   cryo 
preserving medium (Cryo-SFM, Promocell) at a concentration of 1-4 X 106/ml. Cell 
suspension was divided into aliquots and frozen at -80ºC. Cells were transferred to liquid 
nitrogen for extended storage. Thawing of cells for use was performed by placing the 
cryo-vials in a 37ºC water bath until the frozen suspension is close to melting and 
swirled slowly by hand until cell suspension is completely thawed. Vials were sprayed 
briefly with 70% ethanol to avoid contamination then cells were transferred in a culture 
flask with fresh pre-warmed media, placed in the incubator overnight and the medium 
replaced to remove floating dead cells. 
 
 
2.3     Cell Counting 
 
 
2.3.1 CASY 1 Cell Counter  
 
Cell numbers were determined using a CASY 1 TT cell counter and analyzer (Schärfe 
system, GmbH). Prior to counting, a cleaning cycle was performed with Phosphate 
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buffered saline to clear carry-over background. Using the cell counter appropriate cup 
(CASYcup), 400 μl of sample was used and diluted to a volume of 10 ml with PBS. 
Samples were run 3X and reported as number of cells per ml.   
 
2.3.2 Haemocytometer  
 
Cells were diluted as appropriate with 0.4% Trypan blue solution (Sigma) in total of 200 
μl. Cell suspension was pipetted (approximately 10 µl) at the edge of the cover-slip and 
allowed to run onto the haemocytometer. Excluding dead cells (stained with trypan 
blue), the average number of cells in one large square x dilution factor x 104 = number of 
cells per ml. 
 
 
2.4 Transfection of Cells 
 
  
2.4.1 Plasmid DNA Transfection 
 
HeLa cells and MCF-7 cells were transfected using Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacturer’s instruction. Cells were seeded out (2x106 
per 100 mm plate) and left to adhere overnight. DNA (0-1.5 µg) and Lipofectamine 
2000 were mixed separately in serum-free media before being combined to a total of 1 
ml per 10 cm plate. Combined DNA and the transfection reagent were incubated at room 
temperature for 20 minutes to allow complexes to form. Meanwhile, cells were washed 
once in PBS and 5 ml of serum-free media was added. Complexes were then added drop 
wise to the cells and left to incubate for 4-5 hours at 370C. Following incubation cells 
were then washed and fresh complete media was added. After 24-48 post-transfection 
cells were washed with PBS and either lysed or incubated in serum-free media for 16-24 
hours prior to stimulation. 
 
 
2.4.2 RNA interference (RNAi) 
 
HeLa cells were transfected using Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instruction. Cells were seeded out (1x106 per 60 mm plate) and 
grown overnight. Short RNAi oligomers were diluted with appropriate buffer (siRNA 
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Dharmacon buffer) to a stock of 20 µM stock. SiRNA and Lipofectamine were mixed 
separately with serum-free media for 5 min at room temperature. Combined siRNA-
Lipofectamine master mix to a total of 500 µl was incubated for 20 minutes. Cells were 
washed and 2.5 ml of serum-free medium was added. Following incubation, siRNA 
master mix was added drop wise to each plate (total siRNA 100-140 pmol/ plate) and 
incubated for 5 hours at 370C. After incubation, the medium was changed to fresh 
complete media.   After 24h-post transfection cells were washed with PBS and either 
lysed or incubated in serum-free media for 24 hours prior to stimulation.  
 
 
2.5     Propagation and Preparation of plasmid DNA 
 
 
2.5.1 Transformation of competent cells 
 
50-100 µl of competent E. coli were thawed on ice and 0.5-1.0 µg plasmid-DNA was 
added. Cells were incubated for further 30 minutes, heat-shocked at 42°C for 45 seconds 
and immediately put back on ice for 2 minutes, and 1 ml of LB-medium was added and 
cells were shaken at 37°C for 1 hour. Thereafter, 100 µl of the suspension were plated 
on an antibiotic-containing LB-plate and incubated overnight at 37°C. Colonies were 
picked from plates and used in overnight cultures for DNA purification using the Qiagen 
plasmid miniprep or maxiprep kits.  
 
2.5.2 DNA purification and verification 
 
Plasmid Kits (Maxi or Mini) to isolate DNA are used prior to sequencing for verification 
(primers are listed on Chapter 2.1). Briefly, an alkaline lysis of cells is followed by the 
binding of the plasmid-DNA to an anion-exchange resin while the supernatant passes 
through by gravity flow. RNA, proteins and other impurities are removed in salt washes 
and the purified DNA is eluted with high salt conditions. To precipitate the DNA, ice-
cold 100% isopropanol was added and centrifuged. The supernatant was discarded and 
the DNA pellet washed with 70% ethanol and air-dried. DNA is resuspended in sterile 
distilled H2O or TE buffer (10 mM Tris-HCl pH 7.4, 1mM EDTA) and stored at 4ºC. 
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Sequencing to verify expression plasmid was performed by the Beatson Institute for 
Cancer Research, Glasgow, UK. DNA concentration was determined by measuring 
absorbance at 260 nm. 
 
 
2.5.3 Subcloning of Plasmids  
 
The plasmids used were gifts from Dr. David Mattalanas (pCDNA3.1 HA-RASSF1A, 
pcDNA3.1 Flag-MST2, pRK5 Myc-CNK1/ pRK5 empty vector), Dr. David Romano 
(pCDNA3.1 mRFP-Raf-1) and pCDNA3.1 vector (Ms. Joan Grindlay) from Beatson 
Institute, Glasgow, UK/ University College Dublin/ Conway Institute, Ireland). Plasmid 
pRK5Myc-CNK1 was subcloned to pCDNA3.1 vector for in vitro Transcription/ 
Translation. To create an expression vector for the production of pCDNA3.1-CNK1, 
CNK1 was removed from pRK5 using flanking restriction sites BamH1-EcoR1. The 
restriction digest from vectors was run on an 1% agarose gel and the resulting cDNA 
fragment was isolated using an Agarose Gel Extraction Kit (QIAEX II, Qiagen) as 
directed by the manufacturer. Ligation of DNA was performed by mixing vector DNA 
(pCDNA3.1), insert DNA (CNK1), ligation buffer and T4 ligase both from Promega. 
Ligation reaction mixture was incubated for 2 hours at room temperature. The construct 
was transformed into E-coli OneShot TOP10 (Invitrogen) competent cells. Overnight 
cultures were prepared from clones and plasmid mini or maxi preps were carried out. 
Constructs were verified by sequencing using pCDNA3.1 specific primers (T7 sequence 
in Chapter 2.1). 
 
 
2.6     In vitro Transcription-Translation 
 
 
Proteins were synthesised in vitro using a TNT Quick Coupled Transcription/Translation 
Kit (Promega) following the manufacturer’s protocol. TNT Quick Master Mix was 
rapidly thawed by hand and placed on ice. Components of TNT Reactions were all 
assembled on ice. In a reaction tube, a mixture of 40 µl of TNT T7 Quick Master Mix, 2 
µl of 1 µg plasmid DNA and 2 µl of [35S] labelled-methionine were added to a total 
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volume of 50 µl with nuclease-free water. TNT Reaction mixture was gently mixed and 
incubated at 30ºC for 90 minutes. 5-10 µl of each sample was analysed by SDS-PAGE. 
Subsequently, the gel was dried and visualised by autoradiography. 
 
 
2.7     Peptide Array 
 
Cellulose membrane spotted with overlapping synthesised 25-mer peptides from human 
CNK1, off-set by five amino acids were obtained from Prof. Miles Houslay (College of 
Medical, Veterinary and Life Sciences, University of Glasgow). The array was blocked 
in 5% BSA for 1 hour at room temperature. Radioactive labelled protein (by In vitro 
Transcription/ Translation) was added on the peptide array and incubated in a rotator for 
2 hours at room temperature. After incubation, the blot was washed 4-5X with TBST for 
5 minute each wash. Finally, the peptide array was exposed on film. To be re-probed, the 
blot was stripped using a buffer containing 20mM DTT, 70mM SDS and 70mM Tris 
(pH 6.8) for 1 hour.    
 
 
2.8     Site-directed Mutagenesis 
 
 
Mutant forms of CNK1 were synthesised using a QuickChange II site-directed 
mutagenesis PCR kit from Stratagene according to manufacturer’s instructions and with 
primers listed in Chapter 2.1. Briefly, a reaction mixture of DNA template, 
oligonucleotide primers, dNTP mix, DNA polymerase, reaction buffer in sterile distilled 
water was prepared to a volume of 50 µl. PCR programs used are as follows: 95ºC 30 
sec, 55ºC 1 min, 68ºC 15 min and cycle was repeated 15X. After PCR, the reaction 
samples were digested with Dpn I restriction enzyme for 1 hour at 37ºC. DNA from each 
sample was transformed (see Transformation of competent cells), purified and was 
confirmed for the presence of mutation by DNA sequencing.   
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2.9     Western Blotting 
 
 
2.9.1 Preparation of Cell Lysates 
 
Incubated cells (transfected and/or treated/ untreated) were washed once with ice-cold 
PBS and lysed in buffer containing 20mM HEPES, 0.5mM EGTA, 0.5mM EDTA, 1% 
NP40 (v/v) and 150mM NaCl supplemented with protease and phosphatase inhibitors (1 
mM PMSF, 2mM NaF, 1mM sodium orthovanadate, 2.2 µg/ml aprotinin, 2mM sodium 
pyrophosphate, 5 µg/ml leupeptin, 10mM β–galactosidase) or Complete protease 
inhibitor cocktail tablet/ PhosSTOP phosphatase inhibitor cocktail tablet from Roche.  
Lysed cells were scraped using a cell scraper and transferred to 1.5 ml microcentrifuge 
tubes on ice and vortexed. The microcentrifuge tubes were centrifuged at 14000 rpm at 4 
°C for 8 minutes. The supernatants were transferred to a fresh microcentrifuge tube and 
either resolved by SDS-gel electrophoresis or immunoprecipitated. 
 
2.9.2 SDS-PAGE 
 
Proteins from lysates and immunoprecipitates were resolved in denaturing sodium 
dodecyl sulphate polyacrylamide (SDS-PAGE) gels according to molecular weight. 
Either pre-cast Invitrogen NuPAGE Novex 4-12 % Bis-Tris gels in a Novex XCell 
SureLock Mini-Cell Module system along with reagents (4X NuPAGE® LDS Sample 
buffer, MOPS Running Buffer) was used or manually made gels using Amersham 
Pharmacia mini-gel caster [10% acrylamide (v/v), 2mM EDTA, 0.33mM Tris pH 8.9, 
0.07% ammonium persulphate (w/v), 0.1% TEMED (v/v)]. Distilled water was pipetted 
to cover the gel. Once the gels were set, excess water was removed using Whatman 
3MM paper. 5% acrylamide stacking gels [5% acrylamide (v/v), 125 mM Tris pH 6.8, 
4mM EDTA, 0.1% SDS (w/v), 10 % ammonium persulphate (w/v)] were poured on top 
of the polymerized gel, a comb inserted and allowed to set. Prior to loading of samples, 
5X  Laemmli sample buffer [62 mM Tris pH 6.8, 2% SDS (w/v), 10% Glycerol (v/v), 
0.1% bromophenol blue (w/v), 0.5M DTT] was added to the sample and boiled (100 °C) 
for 5 minutes to denature protein. The precision plus dual colour protein standard from 
BioRad was used to estimate molecular weights of the proteins of interest. 
Electrophoresis was performed in 1X SDS-PAGE running buffer (25mM Tris, 192 mM 
  64
glycine, 0.1% SDS w/v) at an initial voltage of 100V. Once bromophenol blue dye had 
passed through the stacking gel, the voltage was set to 140V for 1 to 1.5 hours. 
  
2.9.3 Immunoblotting 
  
Following resolution of proteins by electrophoresis, proteins were transferred to a PVDF 
membrane (Hybond-P, Amersham Pharmacia) using an Invitrogen Novex XCell II Blot 
Module system along with reagents (NuPAGE® Transfer Buffer) or Biorad Transblot 
electrophoretic transfer cell system. The membrane was soaked in methanol and placed 
on the gel sandwiched with Whatmann 3MM paper and sponge and set in a transfer 
blotting cassette. Transfer was carried out in 1X Transfer buffer [200 mM Glycine, Tris 
25 mM, 20% methanol (v/v), 0.01% SDS (w/v)] at 30V for 2 hours. After transfer, 
membranes were blocked with 5% Roche blocking buffer in 1X TBST for 1 hour at 
room temperature with gentle rotation. The membrane was then incubated with relevant 
primary antibodies for 2 hours at room temperature or overnight at 4 °C diluted with 
blocking buffer. The primary antibodies utilised for western blotting are listed in 
Chapter 2.1. The membranes were then washed 3X with TBST for 10 minutes each to 
remove excess primary antibody and incubated with appropriate horseradish peroxidise-
conjugated secondary antibody (1:10,000 dilution with TBST) for 1 hour at room 
temperature. After 3X 10 minute washes with TBST, bands were detected using 
enhanced chemiluminescence (ECL) method and exposed to Fuji X-Ray Film. To re-
probe, membranes were stripped with stripping buffer [0.2M glycine pH 2.5, 1% SDS 
(w/v)] or Roche stripping buffer for 30 minutes and re-blocked before incubating with 
another primary antibody. 
 
 
2.10     Immunoprecipitation  
 
 
Lysates were obtained as described above. A small sample (5%) of lysate was set aside 
to resolve on a gel. The remainder of the lysates were transferred to a separate eppendorf 
tube and kept on ice. Meanwhile, protein G sepharose beads (Sigma) were washed 2X 
with lysis buffer and resuspended to 50% slurry with lysis buffer. Lysates were 
precleared with 50 μl of the 50% slurry and rotated for 30-60 minutes at 4°C. After 
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preclearing, beads were pelleted by centrifugation at 14000 rpm for 45 seconds at 4°C. 
Precleared lysates were transferred into new sample tubes and 1-2 μl of antibody were 
added to each tube and rotated at 4°C for 3 hours. After the incubation, 30 μl of the 50% 
slurry beads were added and rotated for another 1 hour at 4°C. After the incubation, the 
beads were pelleted by centrifugation at 12000 rpm for 45 seconds at 4°C. The beads 
were then subjected to three washes with lysis buffer (beads pelleted at 12000 rpm for 
45 seconds at 4°C). After aspiration of last wash, bead bound immunoprecipitates were 
released by the addition of equal volume of 5X sample buffer [62 mM Tris pH 6.8, 2% 
SDS (w/v), 10% Glycerol (v/v), 0.1% bromophenol blue (w/v), 0.5M DTT] or  4X 
NuPAGE® LDS Sample buffer. Samples were heated to 100°C for 5 minutes and 
analysed by SDS-PAGE and Immunoblotting. 
 
 
2.11     In-Gel kinase Assay  
 
 
MST2 immunoprecipitates were separated by SDS PAGE co-polymerised with 
0.5mg/ml myelin basic protein (MBP). To control for autophosphorylation, samples 
were resolved in parallel on gels not containing MBP. Resolving gel was placed in 50 ml 
of SDS removal solution [20% 2-propanol (v/v), 50 mM Tris pH 8.9], agitated gently for 
20 minutes, 3X at room temperature. Succeeding steps were all performed at room 
temperature unless specified. Gels were washed 3X in a solution of 50 mM Tris pH 8.0 
with 5 mM β–mercaptoethanol for 20 minutes. The proteins were denatured by 
incubating the gel in 50 ml of denaturation buffer (6M guanidine HCl, 50 mM Tris pH 
8.0, 5 mM β–mercaptoethanol) for 1 hour. The proteins were renatured by incubating the 
gel in 50 ml of renaturation buffer [50 mM Tris pH 8.0, 5 mM β–mercaptoethanol, 
0.04% Tween-20 (v/v)] for 60 minutes at 4°C 2X. The renaturation buffer was replaced 
with fresh renaturation buffer and left at 4°C agitated overnight. The following day, the 
gel was washed with 40 mM HEPES pH 8.0, 10 mM MgCl2 with 2 mM DTT for 1 hour 
at room temperature. Phosphorylation reaction was carried out by incubating the gel in 
10 ml of 40 mM HEPES pH 8.0, 10 mM MgCl2, 0.5 mM EGTA, 50 μM ATP and 25 
µCi [ -32P]ATP for 2 hours at room temperature. The gel was washed 10X to stop the 
reaction with a solution containing 5% trichloroacetic acid (w/v) and 1% sodium 
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pyrophosphate (w/v). Finally, the gel was dried onto Whatmann 3MM and analyzed 
using a phosphorimager. 
 
 
2.12     Fluorescence Activated Cell Sorting (FACS)  
 
 
Cells were grown, transfected and treated as required. The cell culture medium 
containing detached cells was collected in a 15 ml conical tube. Adherent cells were 
trypsinised [0.05% trypsin (v/v), 0.02% EDTA v/v), in DMEM, obtained from Gibco] 
and resuspended in fresh growth medium and combined with the medium from the same 
sample. A small aliquot of this cell suspension was run in a CASY 1 Cell Counter to 
determine relative cell number on each sample. The remaining cell suspension was 
centrifuged (1000 rpm for 7 minutes and washed once in ice-cold PBS and 
resuspended.in 200 μl PBT [(PBS pH 7.4, 0.5%BSA (v/v), 0.1% Tween-20 (v/v)]. Cells 
were fixed with the addition of 1.8 ml of 4°C 70% ethanol while slowly vortexing and 
were incubated for at least 1 hour or overnight at 4°C. After fixing, cells were 
centrifuged and supernatant were discarded. Cells were incubated with 300 μl of staining 
solution containing 250 μg/ml of RNAse (Qiagen) and 10 μg/ml of propidium iodide 
(Molecular Probes) for 30 minutes at room temperature in the dark. After incubation, 
cells were pelleted and resuspended with PBT. Cells were wrapped in aluminium foil to 
protect from light. Analysis was performed on a Becton Dickinson FACScan.  
 
 
2.13     Caspase Assay  
 
The caspase assay was employed to measure caspase activity or apoptotic cells using a 
Caspase-Glo 3/7 assay from Promega that uses a luminogenic substrate containing the 
DEVD sequence. Cells were grown and transfected in a six well plate. Detached and 
undetached cells were collected and washed once with cold PBS. Cells were 
resuspended with PBS and aliquot of cell suspension were counted. 100 μl 1.5 X 104 of 
the cell suspension and PBS (blank) was transferred to a white-walled 96-well plate. 100 
μl of Caspase-Glo 3/7 reagent was added and incubated at room temperature for 2 hours. 
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The luminescence of the samples was measured using a luminometer. The luminescent 
signal is directly proportional to the caspase activity of the cells. 
 
 
2.14     Data and Statistical Analysis 
 
Data are presented as mean +/- standard error of the mean (SEM) unless otherwise 
indicated. Student’s test was used for comparisons. Data analysis was performed using 
Microsoft Office Excel. To quantify the bands obtained from Western blot analysis, 
ImageJ software based analysis (http://rsb.info.nih.gov/ij/) was used. 
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CHAPTER 3 
 
 
Scaffold property of CNK1 in the Hippo Tumour 
Suppressor Pathway 
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3.1     Introduction 
 
 
The assembly of signalling molecules, proteins and kinases into a complex by a scaffold 
protein guides an array of cellular decisions. One of the classical properties of a scaffold 
protein is the ability to confer combinatorial inhibition. A simpler model of this 
phenomenon is schematically described in figure 3.A. As described in the previous 
chapter, this phenomenon is also called the prozone effect. This phenomenon stems from 
the precipitin reaction test widely used by immunologists, where increasing amounts of 
antigens added into a series of equal amounts of antibodies results  in a maximum 
precipitate when an optimum antigen-antibody concentration is achieved, and then 
declines at higher antigen titre (Bray and Lay, 1997). Because of the three-dimensional 
lattice of antigen and antibody molecules, it has been posited that a similar effect may 
occur in multimeric protein complexes such as scaffold proteins in cells (Ferrell, 2000; 
Levchenko et al., 2000).  
 
Indeed, insights from computational modelling have provided indispensable conceptual 
recommendations for experimentalists (Endy and Brent, 2001). However, although it is 
difficult to test most of the concepts, progress has been made over the past decade and 
one of the first and best studied examples of the complexity of scaffold protein is Ste5p 
of the yeast Saccharomyces cerevisiae; which is also the most characterized proto-
typical scaffold (Flatauer et al., 2005; Park et al., 2003; Harris et al., 2001). Studies of 
Ste5p established scaffold proteins as physiologically important regulators that bind 
multiple signalling components of the three-tiered mitogen-activated protein kinase 
(MAPK) cascade in yeast (Elion et al., 2005; Morrison and Davis, 2003). Of note, the 
term scaffold protein and adaptor protein are sometimes interchanged to describe 
proteins that function to bind proteins together. In the literature however, adaptor 
proteins are defined as proteins that have a rather limited function, that is to bind 
partners together and localized in specific cellular space (Buday and Tompa, 2010). 
Scaffold proteins, on the other hand, are larger multidomain proteins that assemble 
several components of a signalling cascade such as the MAPK modules for efficient 
transit of signals for proper responses to extra- and intracellular stimuli (Burack and 
Shaw, 2002). 
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Figure 3.A. Prozone effect in comparison to combinatorial inhibition. The 
interaction of antigen and antibody results in lattice formation and production of clumps 
or agglutination thus precipitates as there is equivalence or optimum level of antigen and 
antibody concentration. From the precipitin curve, antigen or antibody excess results in 
lesser or absence of precipitate. This occurs as the Ag-Ab complex is unable to link and 
form large aggregates that are visible as precipitates. The lack of agglutination at high 
concentrations of antibodies is referred to as the prozone effect (Bray and Lay, 1997). 
Meanwhile, combinatorial inhibition refers to weakening of signal transmission due to 
dilution of pathway components. Given that the function of scaffold protein is to 
assemble interacting proteins together, such those of the MAPK cascades, the amount of 
scaffold requires it be titred at optimum levels of the components to which it binds. 
When scaffold concentration exceeds that of the interacting proteins it coordinates, the 
output of the signalling cascade decreases (Levchenko et al., 2000; Ferrell, 2000). It is 
this biphasic effect of scaffold protein via combinatorial inhibition that is analogous to 
the prozone effect of antigen-antibody reaction, hence the appearance of the signature 
“bell-shaped” curve.    
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As the MAPK signalling pathway is conserved from yeast to humans, several data 
suggest that scaffolding proteins similar to Ste5 are likely to play an important role in 
organizing MAPK modules in mammalian cells as well (Dard and Peter, 2006). Indeed, 
mammalian cells appear to employ, at least in part, a similar mechanism to ensure 
efficient complex modes of activation of mammalian MAPK cascades including several 
other non-MAPK-based signalling pathways to execute crucial and diverse cellular 
functions including proliferation, differentiation and apoptosis (Morrison and Davis, 
2003; Yoshioka, 2004; Zeke et al., 2009). However, the number of scaffolds and 
interacting partners that are emerging will likely impose further complexity to the 
regulation of MAPK signalling. In addition, the complexities of scaffold proteins are 
further increased by the functioning of super-scaffolds such as MORG1, which connect 
different scaffolding complexes forming supra-scaffolded protein complexes (Vomastek 
et al., 2004; Kolch, 2005). Therefore, complex mechanisms involving pathway 
integration may also be attributed to scaffold proteins as well. Indeed, cross-talk between 
downstream components of opposing EGFR signalling and the Hippo pathway has been 
demonstrated (O’Neill et al., 2004; Mattalanas et al., 2007). As discussed in detail in 
chapter 1, Raf-1 a main component of the EGFR signalling pathway, and MST2 of the 
apoptotic Hippo pathway was suggested to confer a crosstalk model. The Hippo pathway 
originating from the RASSF1A tumour suppressor in association with MST2 activates 
its substrate LATS1, consequently activating downstream components leading to p73-
mediated transcription of puma that result in apoptosis (Mattalanas et al., 2007). 
However, MST2 which is at the core of this pathway was shown to be negatively 
regulated by the proto-oncogene Raf-1.  
 
Common to this central hub of the pathway, that is Raf-1, and the tumour suppressors 
RASSF1A and MST2 kinase, is their association with CNK1. As previously discussed in 
Chapter 1, CNK1 modulates the tyrosine kinase Src-dependent activation of Raf-1 in a 
concentration dependent manner typical of a scaffold protein and that B-Raf also binds 
CNK1, although the significance of this interaction is unknown (Ziogas et al., 2005). 
CNK1 was also reported to support Ras-mediated apoptosis by its ability to bind the 
tumour suppressor RASSF1A and the pro-apoptotic kinases MST1/2 (Rabizadeh et al., 
2004). As aforementioned, upon serum-starvation Raf-1 associates with MST2 to inhibit 
its activity and its association with RASSF1A independent of Raf-1’s kinase activity 
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(O’Neill et al., 2004; Mattalanas et al., 2007). Recently, it has been demonstrated that 
Akt inhibits MST2 activity and promotes its interaction with Raf-1, while RASSF1A 
overexpression disrupts their interaction (Romano et al., 2010). In addition, other 
RASSF family proteins such as RASSF5/6 regulate MST kinases differently as well 
(Ikeda et al., 2009; Pfeifer et al., 2010).  MST2 cleavage and activation are inhibited by 
IGF1 through the PI3K/Akt pathway (Kim et al., 2010). Alternatively, an unexpected 
positive role of MST2 in the Raf-1/ ERK pathway has been described (Kilili and 
Kyriakis, 2010). Collectively however, the underlying mechanism of Raf-1:MST2 
complex is not yet clear. Indeed, the upstream regulation of these two opposing kinases 
or in-parallel of the Hippo pathway is quite complex and the integration and inducers of 
the Raf-1:MST2 complex in a paradoxical function has yet to be investigated. The 
experiments described in this chapter were carried out in an attempt to examine the 
dynamics of the Raf-1:MST2 complex. Herein, I identified the scaffold protein CNK1 as 
a mediator in the formation and dissociation of this complex and demonstrated a 
possible role of CNK1 in the Hippo pathway apoptotic signalling by its association and 
regulation of its core components.      
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3.2       Results 
 
 
3.2.1   CNK1 mediates MST2 and Raf-1 interaction upon serum   
            starvation in a concentration-dependent manner 
 
 
To demonstrate the proto-typical “bell-shaped” signature of a scaffold protein, it is 
usually accomplished by perturbing endogenous levels by overexpression of the 
particular scaffold and observing a specific pathway output or association of relevant 
signal transduction cascade component. Therefore, a Myc-tagged CNK1 expression 
plasmid was used to transiently increase basal cellular levels of CNK1 into the human 
cervical cancer cell line, HeLa cells, obtain expression of low and high levels of CNK1 
and determine whether ectopically expressed CNK1 can modulate Raf-1:MST2 
complex. Serum deprivation of several cancer cell lines including HeLa cells enhances 
formation of the Raf-1:MST2 complex, preventing MST2 activation and pro-apoptotic 
signalling (O’Neill et al., 2004; Mattalanas et al., 2007; Romano et al., 2010). As 
previously mentioned CNK1 has been implicated to interact with MST2 and Raf-1 in 
separate studies and demonstrated in several human carcinoma cell lines (Rabizadeh et 
al., 2004; Ziogas et al., 2005). However, the requirements for this trimeric interaction 
have not yet been characterised.  
 
In the light of these observations, it is possible that protein scaffold CNK1 is involved in 
this mechanism. Therefore, I assessed whether CNK1 has the ability to manifest scaffold 
behaviour when complexed with its interacting proteins in a dose-dependent fashion 
under this condition.  To obtain different expression levels, we transiently overexpressed 
Myc-tagged CNK1 expression plasmid in an increasing amount (0.1-1.5 µg). As a 
control, a corresponding empty vector was used. HeLa cells were grown overnight in 
serum-containing medium prior to 16-20 hours of serum-deprived culture medium. 
Following serum starvation of 24h post-transfected HeLa cells, endogenous Raf-1 and 
MST2 proteins were immunoprecipitated and examined by western blotting for their 
ability to interact and form a complex when different levels of Myc-CNK1 are 
expressed.  To monitor the different levels of Myc-CNK1 expressed in the cells, total 
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cell lysates were probed with Anti-Myc tag antibody. Equal loading of lysates was 
confirmed by stripping and reprobing membrane blots using an anti-tubulin antibody. 
Western blot analysis under this condition shown in Figure 3.B.I indicates that compared 
to control cells, transfected cells at a low concentration (0.2 µg) of Myc-CNK1 
constructs markedly enhanced the amount of Raf-1 co-immunoprecipitated with MST2. 
However, cells that were transfected with much higher concentration of Myc-CNK1 
constructs (1.5 µg) dissipates this interaction (first panel). This observation was 
confirmed by performing a reciprocal co-immunoprecipitation wherein Raf-1 protein is 
immunoprecipitated instead, and immunoblotted with Anti-MST2 antibody (third panel). 
Consistently, the amount of MST2 co-immunoprecipitated with Raf-1 in the Myc-CNK1 
transfected cells exhibits a concentration-dependent behaviour. Moreover, because this 
change of MST2:Raf-1 complex exhibits a similar pattern dependent on the 
concentration of transfected Myc-CNK1 plasmid regardless from which it has 
precipitated, either IP MST2 or IP Raf-1, I measured the density of the protein bands 
detected on the immunoblots. Figure 3.B.II shows the relative quantification of the band 
intensities immunoprecipitated MST2: Raf-1 interaction from six independent co-
immunoprecipitation experiments. MST2 co-precipitated with Raf-1 immunoprecipitates 
and Raf-1 co-precipitated with MST2 immunoprecipitates from cells transfected with 
increasing amount of Myc-CNK1 plasmid were quantified by densitometry, normalised 
to the empty vector control.  A similar dose-dependent profile was obtained when Myc-
tagged CNK1 expression plasmid was transfected into the human breast cancer cell line 
MCF-7 as shown in Figure 3.B.III.  
 
Taken together, these observations suggest that when cells are deprived of growth 
factors, the scaffold protein CNK1 at a certain optimum level may possibly regulate a 
specific response by forming a discrete signalling component such as a Raf-1:MST2 
complex, thereby facilitating the kinase-independent Raf-1 inhibitory role towards 
MST2. Raf-1, when it complexes with MST2, prevents its dimerization and impending 
pro-apoptotic activation (Mattalanas et al., 2007). In contrast, higher expression of 
CNK1 dissociates this complex. As a consequence, upon release from Raf-1, free MST2 
may then be available for activation upon stress signals or pro-apoptotic stimuli such as 
serum starvation. Indeed, in response to Fas and serum starvation, Raf-1 -/- mouse 
embryo fibroblasts are sensitive to apoptosis with an increase in MST2 activity (O’Neill 
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et al., 2004). MAPK scaffold proteins might either facilitate or inhibit signalling 
depending on their concentration, thus producing a bell-shaped concentration response 
curve (Yoshioka, 2004; Kolch 2005). The graph in Figure 3.B.II shows the relative 
quantitation of band intensities of either MST2 or Raf-1 immunoprecipitates suggests a 
proto-typical scaffold property of a ‘bell-shaped’ signature. Consistent with the idea of 
multimeric protein complexes are formed through scaffold proteins, the results indicate 
that CNK1’s ability to exhibit a bimodal regulation is possibly by assembling an 
inhibitory Raf-1:MST2 complex conferring negative signalling at an optimal expression, 
but when expressed at higher levels, it disperses this complex by titrating the 
components freeing MST2 for activation, therefore promoting positive signalling. 
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Figure 3.B CNK1 mediates MST2 and Raf-1 interaction upon serum-starvation in a 
concentration-dependent manner. 
 
 
I 
 
 
 
II 
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Figure 3.B. CNK1 mediates MST2 and Raf-1 interaction upon serum-starvation in 
a concentration-dependent manner. (I) HeLa cells were transiently transfected using 
an increasing amount of Myc-tagged CNK1 expression plasmids (0.1-1.5 µg Myc-
CNK1 DNA concentration) and empty vector. After 16-20hr serum-starvation, 
endogenous MST2 and Raf-1 immunoprecipitates were prepared, subjected to SDS-
PAGE followed by western blotting and probed with indicated antibodies. Anti-Myc was 
used to monitor the amount of expressed Myc-CNK1, and anti-tubulin for loading 
control of proteins is shown in the lower panel. (II) The band intensities of Raf-1:MST2 
interaction from the immunoblots of six dose-dependent Myc-CNK1 overexpression co-
IP experiments (three Raf-1 immunoprecipitates from MST2 co-IP experiments and 
three MST2 immunoprecipitates from Raf-1 co-IP experiments) were quantified by 
densitometry and were normalised to the control. Results are expressed as mean +/- 
SEM, n=3, *P=<0.05, ** P=<0.005, n.s. P= >0.05. Densitometry of immunoblot band 
intensity was performed using Image J software from National Institutes of Health. (III) 
Transfection of MCF-7 cells was performed in a similar manner as the HeLa cells. 
Following serum starvation, cells were lysed and MST2 and Raf-1 immune complexes 
were analysed by western blotting and probed with indicated antibodies. Cell lysates 
were probed with antibody recognising the Myc tag to determine Myc-CNK1 expression 
and with antibody directed against tubulin as control for loading of proteins.  
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3.2.2 CNK1 affects interaction of MST2 kinase and its substrate  
             LATS1 
 
 
As discussed in Chapter 1, components of the Hippo pathway that include MST1/2, 
LATS1/2, and YAP are highly conserved in mammals. These are Hpo, Wts and Yki 
Drosophila homologs respectively (Edgar, 2006; Avruch et al., 2011). Pioneering work 
in Drosophila has established the Hippo pathway as a key regulator of the cell cycle, 
apoptosis and development; and importantly, in human cells a very similar signalling 
module exists (Harvey et al., 2003; Jia et al., 2003; Udan et al., 2003; Wu et al., 2003). 
Although it is now firmly established that the Hippo pathway is a tumour suppressor 
pathway that restricts cell cycle progression and proliferation and promotes apoptosis; 
new components and new molecular interactions are continuously being added to the 
pathway (Harvey and Tapon, 2007; Bao et al., 2011). An emerging theme is the 
regulation of the core components by different upstream protein complexes (Grusche et 
al., 2010). A mammalian model proposed, as described in chapter 1, is the induction of 
apoptosis via activation of LATS1 by MST2 mediated by RASSF1A upon apoptotic 
stimuli (Mattalanas et al., 2007) intriguingly all are tumour suppressors.  
 
In light of the above findings that the Raf-1:MST2 complex may possibly be mediated 
by CNK1 in a concentration-dependent fashion and because LATS1 is a direct substrate 
of MST2, further examination of the MST2 and LATS1 interaction is warranted. 
Therefore, I set-out to perform similar experiments as described above, i.e. to 
overexpress myc-CNK1 in increasing amount (0.1-1.5 µg Myc-CNK1 DNA 
concentration) in HeLa cells including empty vector (pcDNA3) as a control and to 
determine how the interaction between LATS1 and MST2 is altered. Figure 3.C.I (upper 
panel) shows overexpression of Myc-CNK1 mediates the interaction of Raf-1:MST2 
complex in HeLa cells deprived of growth factors in a dose-dependent fashion, 
consistent with the previous experiment (Figure 3.B.I). Interestingly, MST2 precipitates 
subjected to western blotting using an anti-LATS1 antibody indicate that the MST2 and 
LATS1 interaction was decreased in an intermediate CNK1 expression but increases as 
higher concentrations of Myc-CNK1 protein is expressed compared to control (Figure 
3.C.1 third panel). Reciprocal co-immunoprecipitation shows that when LATS1 
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precipitates are probed with anti-MST2, the amount of MST2 detected is altered 
dependent on the amount of CNK1 expressed, in a manner consistent with the MST2 IP. 
Here, the results indicate that release of MST2 from Raf-1 at a higher CNK1 expression 
corresponds to the increased association of MST2 and its substrate LATS1, while 
recruitment of MST2 to Raf-1 mediated by an intermediate CNK1 expression 
corresponds to the decrease in binding of MST2 to LATS1. Further supporting this idea, 
previous reports showed that MST2 when released from Raf-1, promotes LATS1 and 
MST2 association via RASSF1A, allowing LATS1 to phosphorylate YAP1. YAP1 is 
then translocated to the nucleus, resulting in apoptosis of Hela and MCF-7 cells 
(Mattalanas et al., 2007; Kawahara et al., 2008). Together, these data suggest that CNK1 
perturbs the MST2-LATS1 interaction, corresponding to a dose-dependent modulation 
of the Raf-1: MST2 complex. This may show an important role of the scaffold protein 
CNK1 in the regulation of the two core components of the Hippo pathway in apoptotic 
signalling.  
 
 
 
FIGURE 3.C. CNK1 affects interaction of MST2 kinase and its substrate LATS1 
 
 
I.  
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FIGURE 3.C. CNK1 affects interaction of MST2 kinase and its substrate LATS1. 
(I) HeLa cells were transfected with Myc-tagged CNK1 expression plasmid at indicated 
DNA concentrations (0.1-1.5 µg Myc-CNK1) including an empty vector as a control. 
Following 16-20hr serum starvation, endogenous Raf-1 and MST2 immunoprecipitates 
were performed in accordance with the co-immunoprecipitation assay as described in the 
experimental procedures (Chapter 2). Protein interactions were determined by western 
blot with indicated antibodies. Western blot image is a representative of two independent 
experiments. (II) Reciprocal co-immunoprecipitation wherein LATS precipitates 
immunoblotted with anti-MST2 shows consistently the interaction of LATS1 and MST2 
is affected by CNK1 levels in HeLa cells. Aliquots of cellular lysates were examined to 
monitor increasing expression of CNK1 levels using an anti-Myc tag antibody and by 
using anti-tubulin antibody as a loading control.  
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3.2.3    Levels of CNK1 affect MST2 phosphorylation  
 
 
 
Kinase activity is a key biochemical property of protein kinases that are involved in all 
fundamental properties in the cell (Johnson and Hunter, 2005). Kinases can be turned on 
or off by phosphorylation by binding of activator proteins, inhibitor proteins, small 
molecules, or linker proteins such as scaffold proteins, or by controlling their location in 
the cell relative to their substrates (Enslen and Davis, 2001; Bardwell et al., 2001; 
Manning et al., 2002). Phosphorylation by protein kinase is one of the most common 
mechanisms in eukaryotic cells; hence it forms the basis of cell signalling networks 
(Yaffe and Elia, 2001). The protein kinase MST1/2, similar to other kinases, is complex 
and subjected to post –translational modifications. Although, the MST1/2 kinases have 
been shown to be regulated by several mechanisms, including phosphorylation, 
dimerization, proteolysis and protein-protein interaction, the integration of these 
mechanisms of action is still unclear (Creasy et al., 1995; Callus et al., 2006; Praskova et 
al., 2008; Zhao et al., 2008). Moreover the role of interacting partners such as the 
scaffold CNK1 in the regulation of its phosphorylation and activity has not been 
investigated. Furthermore, Raf-1 when complexed with MST2 inhibits its 
phosphorylation and kinase activity (O’Neill et al., 2004), and in the light of our finding 
that CNK1 may play a role in the MST2: Raf-1 complex formation, it is conceivable that 
CNK1 may also be involved in this mechanism.  
 
Thus, I next investigated whether the phosphorylation state of MST2 is influenced by the 
perturbation of the MST2: Raf-1 complex dependent on Myc-CNK1 expression levels. 
As before, HeLa cells were transfected with increasing amounts of Myc-tagged CNK1 
expression plasmids (0.02-1.5 µg Myc-CNK1) including empty vector as control. 
Following serum starvation, endogenous MST2 was immunoprecipitated and then 
subjected to western blotting. MST kinase is phosphorylated at multiple sites, including 
key threonine residues in the activation loop which are critical role in its activation; 
hence, phosphorylated MST2 was detected with an antibody to phosphothreonine 
(Glantschnig et al., 2002, Deng et al., 2003; O’Neill et al., 2004). As shown in Figure 
3.D, Western blotting of MST2 immunoprecipitates in lysates of control cells  showed 
that at endogenous CNK1 levels, a modest amount of Raf-1:MST2 complex forms (third 
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panel), which corresponds to a basal MST2 kinase phosphorylation (fifth panel). 
However, in cells transfected at low concentration of myc-CNK-1 plasmid (0.05-0.5 µg 
DNA) enhanced Raf-1:MST2 formation and corresponded to attenuated MST2 kinase 
phosphorylation. Whereas, in cells transfected at a higher concentration of myc-CNK1 
plasmid (1.5 µg DNA) which dissociates the Raf-1:MST2 complex corresponded to 
elevated levels of phosphorylated MST2. As a control, reciprocal Raf-1 
immunoprecipitates were also analysed and probed for anti-MST2 (first panel) to show 
the Myc-CNK1-concentration mediated perturbation of the Raf-1:MST2 complex, as 
previously shown (Figure 3.B.I). Also as predicted, smaller increment titration of Myc-
CNK1 plasmid levels has flattened the ‘bell-shaped’ curve obtained using myc-CNK1 to 
scaffold the formation of the Raf-1:MST2 complex as illustrated in Figure 3.D. This 
suggests that the Raf-1:MST2 complex is sensitive to expression levels of CNK1. This is 
consistent with previous observations that phosphorylation of MST2 is dampened when 
complexed with Raf-1 (O’Neill, et al., 2004; Mattalanas et al., 2007; Romano et al., 
2010). Together, this data indicates that CNK1 may play a role in MST2 regulation, as 
CNK1 could influence the Raf-1: MST2 complex dependent of its expression levels. 
Therefore, it will be important to confirm this finding by analysing MST2 kinase activity 
under this condition. 
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FIGURE 3.D. Levels of CNK1 affect MST2 phosphorylation 
 
 
 
 
 
 
FIGURE 3.D. Levels of CNK1 affect MST2 phophorylation. HeLa cells were 
transfected with the Myc-CNK1 expression plasmid at the indicated DNA 
concentrations including an empty vector as a control. Following serum starvation for 24 
hours, the cells were then lysed and equal amounts of proteins were subjected to 
immunoprecipitation (IP MST2 and IP Raf-1) and immunoblotted with indicated 
antibodies. Cellular extracts were examined for the increasing expression of CNK1 
levels using anti-Myc, and anti-tubulin as a loading control. The ratio of pThreo to total 
MST2 was quantified by densitometric evaluation of Western blots. The data represent 
the means ± the SEM of three independent experiments,*P < 0.05. 
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3.2.4    Levels of CNK1 affect serum-starvation induced  
             apoptosis 
 
 
Components of the Hippo pathway are deregulated in cancer due mostly to epigenetic 
inactivation of tumour suppressors such as RASSF1A in hepatocellular carcinoma, 
MST1/2 kinases in soft tissue sarcomas, and LATS1/2 kinases in breast cancers (Calvisi 
et al., 2006; Macheiner et al., 2006; Seidel et al., 2007; Takahashi et al, 2005). However, 
at this moment the extent to which the Hippo pathway components vary in terms of 
tissue specificity and frequency, including alterations in expression and specific roles in 
cancer, is yet to be clarified. For example, suppression of Hippo/ MST2-mediated 
apoptosis can be elicited by either inhibition of MST2 phosphorylation by AKT kinase 
or interaction of MST2 with the proto-oncogene Raf-1 in several cancer cell lines 
(O’Neill et al., 2004, Jang et al., 2007). More importantly, the biochemical mechanism 
of the two core Hippo components MST1/2 and LATS1/2 activation by upstream 
effectors to mediate apoptosis in response to cellular environmental stress in several cell 
lines is less well defined, and thus requires further investigation (Avruch et al., 2011).  
 
Hippo/MST-mediated apoptosis is brought about via RASSF1A’s activation of MST2 
upon release from Raf-1, promoting MST2’s downstream phosphorylation of LATS1. In 
turn, YAP1 becomes phosphorylated by LATS1, dissociates from LATS1 and then 
translocates to the nucleus to form a complex with p73, ultimately leading to 
transcription of PUMA which results in apoptosis (Mattalanas et al., 2007). 
Interestingly, p73’s activation of PUMA, independent of p53, has been shown to be 
induced by serum starvation in several colon cancer cell lines, triggering apoptosis 
(Ming et al., 2008).  It is unclear, however, how specific phosphorylation responses and 
interactions of opposing MST2 and Raf-1 kinases are controlled, that trigger eventual 
activation of downstream signalling and ultimately promote apoptosis. Data 
demonstrated so far suggests a possible upstream mechanism which coincides with this 
model; that is, CNK1 concentration-dependent assembly or disassembly of a Raf-
1:MST2 complex corresponds to MST2 activity and downstream formation of a 
MST2:LATS1 complex. Thus, the immediate question to ask was if this regulation of 
the Raf-1:MST2 complex, MST2 phosphorylation and MST2 interaction with its 
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substrate LATS1 have functional consequences in Hippo pathway-mediated, serum-
starvation induced apoptosis.  
 
To determine this, HeLa cells that were subjected to different levels of overexpression of 
CNK1 in similar experiments to those described above (Figure 3.D) were set-up and 
analysed for apoptotic activity. This was done by measuring the sub-genomic DNA 
content of apoptotic cells using the FACS (Fluorescence activated cell sorting) 
technique, as the presence of fragmented DNA in cell is a key hallmark of apoptotic cell 
death (Kitazawa et al., 2002). HeLa cells were transfected with increasing amounts of 
Myc-CNK1 as indicated.  Serum-starvation was extended to 36 hours post-transfection 
to stimulate apoptosis. Figure 3.E. shows that apoptosis of cells which were minimally 
transfected with Myc-CNK1 plasmid (0.1 µg Myc-CNK1 DNA) compared to basal cells 
was decreased that shows a baseline of 5-7% apoptosis, while apoptosis in cells 
transfected with higher levels of Myc-CNK1 plasmid (1.5 µg Myc-CNK1 DNA) 
increased compared to cells transfected at lower levels, but to a modest increase in cells 
at endogenous basal levels under this condition. The data indicate that expression levels 
of CNK1 affects serum-starvation induced apoptosis of cells. Although perturbation of 
CNK1 expression levels may also trigger other non-hippo/MST2 signalling pathways 
that are involved in regulating apoptosis, This data suggests that following stress stimuli 
such as growth factor withdrawal of cells by serum starvation, CNK1 when expressed at 
low level may be able to rescue cells from undergoing apoptosis by binding Raf-1 to 
MST2 in order to sequester MST2 from activation. However, titration of the Raf-
1:MST2 complex caused by elevated levels of CNK1 expression may result in the 
disruption of the complex, liberating MST2, which can then be activated and interact 
with its substrate LATS1 to promote apoptosis. 
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FIGURE 3.E. Levels of CNK1 affect serum-induced apoptosis. 
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FIGURE 3.E. Levels of CNK1 affect serum-induced apoptosis. Hela cells were 
transfected with increasing amounts of Myc-CNK1 as previously described. To induce 
apoptosis, cells were serum-starved for 36 hours post-transfection. Both detached and 
attached cells were collected and an aliquot of cells was stained with hypotonic PI 
(Propidium Iodide)-stain solution. Percent apoptotic cells were assessed using propidium 
iodide incorporation into fragmented DNA and quantified with FACSCAN flow 
cytometer. Graph shows fold changes of apoptosis relative to control. Statistical analysis 
were carried-out using Student’s t test; n=3, error bars indicate mean ± SEM, *p<0.05. 
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3.2.5 CNK1 links MST2 and Raf-1 to modulate Hippo pathway-   
             mediated apoptosis  
 
 
As described in Chapter 1, scaffold proteins function as modulators of signal 
transduction by linking proteins into close spatial proximity to facilitate functional 
protein-protein interactions. Therefore, it is plausible that reducing endogenous CNK1 
levels under similar conditions used in previous experiments should disrupt the Raf-1: 
MST2 complex. The disruption of this complex will allow free MST2 to signal 
downstream of the Hippo pathway and elicit apoptosis. To determine this, we employed 
siRNA-mediated knock-down of endogenous CNK1 expression. HeLa cells were also 
transfected with a scrambled, non-targeting siRNA to serve as a negative control and an 
siRNA pool specific to CNK1 at two different concentrations (120 and 140 pM) by 
lipofectamine as described in Chapter 2. Cells were serum-starved for 24 hours 
following transfection similar to previous experimental conditions. These cells were 
lysed and subjected to immunoprecipitation using Raf-1 or MST2 antibodies, as 
described before.   
 
As demonstrated in Figure 3.F.I, introduction of siRNAs targeting the CNK1 gene, 
unlike control siRNA, reduced the expression levels of endogenous CNK1 (bottom 
panel), more so at an siRNA concentration of 140 pM. The depletion of endogenous 
CNK1 levels in HeLa cells disrupted the Raf-1 and MST2 interaction (first panel) from 
Raf-1 immunoprecipitates. Reciprocal co-immunoprecipitation confirms the disruption 
of the Raf-1:MST2 interaction (third panel). These data suggest that the scaffold protein 
CNK1 is necessary to link Raf-1 to MST2. As the dissociation of Raf-1:MST2 complex 
results in MST2 phosphorylation (Figure 3.D) and activation (O’Neill, et al, 2004; 
Mattalanas et al., 2007), the direct consequence of CNK1 knockdown to this complex, 
i.e. whether it results in MST2 activation, was therefore tested.   
 
Indeed, knockdown of endogenous CNK1 by siRNA augmented MST2 activation as 
indicated by an in-gel kinase assay of MST2 immunoprecipitates (Figure 3.F II, first 
panel). These data suggest that specific knockdown of CNK1 expression by RNAi in 
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HeLa cells results in Raf-1’s dissociation from MST2, which enables free MST2 to be 
activated. Thus, these data indicate that the CNK1 protein levels affect HeLa cells 
response to serum-starvation. Because downregulation of endogenous CNK1 expression 
increases the MST2 kinase activity in response to serum starvation, they also suggest 
that the endogenous levels of CNK1 protein in HeLa cells functions as an inhibitor of 
this response, since its depletion results in increased activation. MST2 kinase when 
activated, dissociates from Raf-1 (O’Neill et al., 2004), then binds (Figure 3.C) and 
phosphorylates its substrate LATS1 for downstream Hippo apoptotic signalling 
(Mattalanas et al., 2007). Further MST2 co-immunoprecipitation experiments in cells in 
which CNK1 expression had been knocked down are shown in Figure 3.F.II (third 
panel). These reveal that dissociation of MST2 from Raf-1, enhanced LATS1 and MST2 
interaction, which corresponds to its increased kinase activity. Collectively, these data 
suggest that Raf-1 requires CNK1 for its inhibitory function towards MST2 activation, 
and may prevent its association to its substrate LATS1, and possibly its activation. 
Hence, it may be important to analyse LATS1 kinase activity under this condition to 
confirm this finding. 
 
As it is well documented that when the Hippo/MST2 pathway is activated via stress 
stimuli it triggers apoptosis of cells (Radu and Chernoff, 2009; Bao et al., 2011) and 
together with the above observations, I sought to measure the apoptotic activity in 
serum-starved HeLa cells in which levels of endogenous CNK1 had been reduced by 
RNAi. Apoptosis was determined by flow cytometric analysis of cell populations with 
sub-G1 DNA content, as previously described. As shown in Figure 3.G (upper graph), 
depletion of CNK1 by RNAi of either concentration (120 pmol/ 140 pmol siRNA-
CNK1) led to significantly enhanced serum-starvation induced apoptosis compared to 
siRNA control cells. Complementary to this, CNK1 knockdown results in the decline of 
cell numbers due to continual cell death by apoptosis as compared to siRNA control 
cells (lower graph). This result suggests that the endogenous level of CNK1 can regulate 
the sensitivity of HeLa cells in response to serum-starvation induced apoptosis. 
 
This model predicts that CNK1 knockdown induction of apoptosis in HeLa cells may be 
dependent on the pro-apoptotic components of the hippo pathway. Therefore, if 
knockdown of associated components, in contrast to CNK1’s effect, will influence this 
response was analysed. A screening RNAi experiment to analyze the efficiency of non-
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targeting siRNAs to MST2 and RASSF1A protein by western blot is shown in Figure 
3.H.I. Next, a caspase-activity –based apoptosis assay was performed as described in 
Chapter 2 (Materials and Methods), to determine the effect of co-knockdown of these 
two proteins in HeLa cells on serum-starvation induced apoptosis. As increased caspase 
activity is a hallmark of apoptosis, the measurement of their levels report directly on 
apoptosis (Degterev et al., 2003; Elmore, 2007). Figure 3.H.II shows that the depletion 
of endogenous CNK1 promoted apoptosis compared to the siRNA control, consistent 
with the previous apoptosis result by FACS analysis in Figure 3.G. In contrast, depletion 
of endogenous RASSF1A and MST2 by siRNA reduced serum starvation-induced 
apoptosis, suggests that both proteins are necessary components of the hippo-pro-
apoptotic pathway and their depletion therefore causes Hela cells to become resistant to 
serum-starvation induced apoptosis. As expected, depletion of Raf-1 promoted apoptosis 
in HeLa cells compared to siRNA control, suggesting that MST2 is free from Raf-1’s 
kinase-independent inhibitory function, therefore sensitizing cells to serum-starvation 
induced apoptosis. Interestingly, co-depletion of CNK1 and MST2 prevented cells from 
apoptosis as there was no significant change compared to control cells, suggesting that 
siRNA-CNK1 induced apoptosis is dependent on the presence of MST2 expression in 
cells. In contrast, co-depletion of CNK1 and RASSF1A still sensitize cells to apoptosis 
suggesting that RASSF1A is negligible in MST2 activation. Meanwhile, co-depletion of 
CNK1 and Raf-1 markedly induced apoptosis compared to control cells including cells 
depleted with Raf-1 alone suggests that both CNK1 and Raf-1 is necessary for MST2 
inhibition and that Raf-1 requires CNK1 to link with MST2 to fully exert its inhibitory 
role. Interestingly, depletion of CNK1 alone compared to Raf-1 seems to be more 
efficient in inhibiting apoptosis. However, Raf-1 siRNA efficiency screening by western 
blot was not performed, therefore confirmation of these results is warranted. Together, 
these finding indicate that CNK1 may play a role in the regulation of the Hippo/MST2 
pro-apoptotic pathway by linking Raf-1 to MST2, facilitating Raf-1’s inhibitory function 
towards MST2, thereby preventing its activation upon apoptotic stimuli.    
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FIGURE 3.F. Depletion of CNK1 impairs Raf-1 and MST2 interaction 
 
I. 
 
II. 
 
 
 
FIGURE 3.F. Depletion of CNK1 impairs Raf-1/MST2 interaction. (I) HeLa cells 
were transfected with a pool of CNK1-specific siRNAs at different concentrations as 
indicated, or with scrambled control siRNA. Following serum starvation and lysis of 
cells, immunoprecipitations of Raf-1 and MST2 proteins were carried out and examined 
by immunoblotting using antibodies as indicated. Cell extracts (TL) were used to 
confirm depletion of CNK1, and anti-tubulin antibody was used as a loading control. (II) 
Similar to the experiments above, following serum starvation for 24 hours, the cells were 
then lysed and equal amounts of proteins were subjected to immunoprecipitation and 
immunoblotted with indicated antibodies. Cellular extracts were examined for the 
increasing expression of CNK1 levels using anti-CNK1, and anti-tubulin as a loading 
control. For the kinase assay, MST2 immunoprecipitates were separated by SDS-PAGE, 
and in-gel kinase assays were carried out with MBP (myelin basic protein, as substrate) 
embedded in the gel as described in Chapter 2 (Materials and Methods). Western blot 
image (I and II) is a representative of two independent experiments. 
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FIGURE 3.G. Depletion of CNK1 induces apoptosis in HeLa cells 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.G. Depletion of CNK1 induces apoptosis in HeLa cells. CNK1 siRNA-
induced apoptosis of serum-starved HeLa cells at indicated concentrations was detected 
by measuring the population of cells containing sub-genomic DNA fragments stained 
with propidium iodide using a flow cytometer (upper graph). Results are expressed as 
mean +/- SEM, n=3, *P=<0.05, Student’s t test. Cell counting was performed and 
calculated electronically using the CASY-1 cell counter and analyzed from the same 
HeLa cells prior to fixation and staining for the flow cytometry apoptosis assay. Results 
are expressed as a percent of the control value: mean +/- SEM, n=3, *P=<0.05, Student’s 
t test. 
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FIGURE 3.H. CNK1 induces apoptosis via Hippo/MST2 components 
 
 
 
I. 
 
 
 
 
 
II. 
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FIGURE 3.H. CNK1 induces apoptosis via Hippo/MST2 pathway components. (I) 
HeLa cells were transfected with siRNA specific to CNK1, MST2, RASSF1A and 
scrambled siRNA control. Whole-cell extracts were prepared, equal amounts of protein 
were separated by SDS-PAGE, and blots were probed with the indicated antibodies to 
show depletion of corresponding protein, or tubulin as a loading control. The data above 
is representative of two independent experiments. (II) As before, HeLa cells were 
transfected with control siRNA or siRNA against individual proteins as indicated, or co-
transfected with CNK1. A caspase 3/7 luminescence assay was used to determine the 
level of caspase activated-based apoptosis as described in Chapter 2 (Materials and 
Methods). The relative luminescent intensity is proportional to the caspase activity 
present in apoptotic cells. Results are expressed as mean +/- SEM, n=5, P values were 
calculated using Student’s t test. 
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3.3       Discussion 
 
 
To better understand the signalling dynamics of protein scaffold CNK1 functions, I 
began the study by investigating the interaction partners of CNK1 involved in the Hippo 
pathway. Previous studies have shown direct interaction between CNK1 and Raf-1, and 
it was demonstrated that Src-mediated activation of Raf-1 is regulated dependent on 
CNK1 concentration in HEK293T cells (Ziogas et al., 2004). It was also reported to 
support Ras-mediated apoptosis by CNK1’s ability to bind the tumour suppressor 
RASSF1A and the pro-apoptotic kinases MST1/2 (Rabizadeh et al., 2004). Meanwhile, 
it was documented that Raf-1 and MST2 bind upon serum starvation, and MST2 kinase 
is inhibited via a mechanism independent of Raf-1’s kinase activity (O’Neill et al., 
2004). As Raf-1 and MST2 are well established binding partners of CNK1, I examined 
whether the physical interaction of endogenous Raf-1 and MST2 upon serum starvation 
is regulated by CNK1.  
 
The results presented here suggest that the scaffold protein CNK1 may play a role in the 
Hippo/MST2 pathway by regulating the interaction of Raf-1 and MST2. When CNK1 is 
expressed at a concentration close to endogenous levels, the Raf-1:MST2 complex is 
increased. However at higher concentrations, the Raf-1:MST2 complex dissipates. 
Although these findings initially seem counterintuitive, they actually support a typical 
behaviour of a scaffold protein as demonstrated among other MAPK scaffolds (Kolch, 
2005; Yoshioka, 2004). Insights from computer modelling studies referred to this dose-
dependent phenomenon as combinatorial inhibition, which refers to the weakening of 
signal due to dilution of pathway components as scaffold concentration exceeds the 
optimum level to bind client proteins for it to interact functionally, hence the appearance 
of the “bell-shaped” curve (Levchenko et al., 2000; Ferrell, 2000). CNK1 modulation of 
Raf-1 and MST2 interaction seems to reveal a similar dose-dependent behaviour (Figure 
3.B). Indeed, functional analyses support this overexpression property of CNK1 in 
context of the regulation of the Raf-1:MST2 complex. Pro-apoptotic MST2 when 
complexed with Raf-1 is prevented from phosphorylation and activation, but when 
liberated, it can be activated and binds to its substrate LATS1 to signal downstream of 
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the pathway and elicit apoptosis of cells (O’Neill et al., 2004; Mattallanas et al., 2007). 
Consistent with this model, the level of CNK1 expression that maximally increased the 
Raf-1:MST2 complex, led to a decreased MST2 and LATS1 interaction (Figure 3.C), 
decreased MST2 kinase phosphorylation (Figure 3.D) and consequently decreased 
proportion of apoptotic cells (Figure 3.E). However, overexpression of CNK1 at a higher 
level that liberates MST2 from Raf-1, resulted in increased MST2 interaction with 
LATS1 (Figure 3.C), restoration of MST2 phosphorylation (Figure 3.D), as well rescue 
of cells from serum-induced apoptosis (Figure 3.E). Consistently, a previous CNK1 
overexpression study using comparatively higher concentration promoted marked 
apoptosis through RASSF1A and MST1/2 in HEK293 cells (Rabizadeh et al., 2004). 
Employing siRNA-mediated experiments further suggests that CNK1 scaffolds MST2 
and Raf-1 to regulate the Hippo/MST pathway dependent on its expression levels. 
Depletion of endogenous CNK1 levels led to disruption of the Raf-1:MST2 complex 
(Figure 3.F) accompanied by enhanced MST2 activity (Figure 3.G), and sensitised HeLa 
cells to serum withdrawal-induced apoptosis (Figure 3.H).  
 
Taken together, these results suggest that CNK1 expression levels may dictate the 
sensitivity of cells towards apoptosis. CNK1 function as an inhibitor and an inducer, 
CNK1 at endogenous and at intermediate expressions act as an inhibitor and at higher 
expressions it acts as an inducer. Consistent with this are other scaffold-like properties 
such that of the scaffold JIP1 which binds protein kinases of the JNK cascade that 
enhances JNK activation, and inhibits the pathway when overexpressed (Whitmarsh et 
al., 1998, 2001). Similarly, KSR1 interacts with Raf-1, MEK and ERK, and depending 
on its expression levels it can either inhibit or enhance ERK activity (Kortum and Lewis, 
2004). Interestingly, CNK1 was demonstrated to bind Raf-1 and Src in HEK293 cells, 
and when CNK1 is overexpressed in low amounts Src-dependent activation of Raf-1 via 
Ras is increased. At a higher level of CNK1 overexpression, this led to loss of Raf-1 
activation (Ziogas et al., 2005).   A distinction between the findings of CNK1 as a 
scaffold protein presented here and from the examples of typical scaffolds described 
above is that, dose-dependent assembly of Raf-1: MST2 complex mediated by CNK1 
results in negative signalling as opposed to positive signalling. Scaffold proteins may 
regulate cell signalling by assembling both positive and negative signalling components 
to confer a specific response (Kolch, 2005; Dhanasekaran et al., 2007). 
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In this context, CNK1 may be partly reminiscent of the even more complex and diverse 
functions of scaffolds like JIP1, where negative and positive proteins modulate its signal 
transmission. JIP1 assembles JNK, MKK7, and mixed lineage protein kinase (MLK) 
proteins to promote the JNK signalling pathway (Whitmarsh et al., 1998, 2001).  
However, a JNK negative regulator, MAPK phosphatase-7, also binds to JIP1 and 
inhibits JNK activation by dephosphorylating JNK (Willoughby et al., 2003). 
Interestingly, CNK1 has also been demonstrated to bind RASSF1A and MST1/2 to 
promote apoptosis (Rabizadeh et al., 2004).  Similar to the scaffold JIP, it is plausible 
that such negative CNK1/Raf-1/MST2/RASSF1A complex or CNK1/MST2/RASFF1A 
positive and/or other independent set of components may exist with CNK1. Indeed, 
scaffold protein functions such that of CNK1 increases the complexity of revealing 
important roles that may be involved in the regulation of Hippo/MST2 pathway. 
Moreover, the mammalian Hippo/MST2 pathway is still a relatively young field, and the 
general mechanisms are still being elucidated (Pan, 2010; Radu and Chernoff, 2009). 
Therefore further studies understanding the role of scaffolding proteins, specifically 
determining interaction sites between relevant proteins and stepwise mechanism of the 
complex formation and dissociation with corresponding biological consequences, is 
necessary. 
 
Nevertheless, our results are consistent with the dose-dependent model effects of a 
prototypical scaffold protein. This model is summarized and illustrated in Figure 3.I., 
whereby relatively small changes in the amount of CNK1 in cells will result in a 
significant enhancement in the Raf-1:MST2 complex, thereby inhibiting the hippo pro-
apoptotic signal. When in excess, CNK1 dilutes-out Raf-1 and MST2 components, 
thereby releasing MST2 to be activated, binding to its substrate LATS1 to relay 
apoptotic signals and eventually triggering apoptosis of cells. Although the signal 
response varies the bell-shaped signature appears to be correlated as the peak falls at 
relatively similar concentration close to basal levels of CNK1, further supporting that 
CNK1 is scaffolding Raf-1 and MST2 and regulating pro-apoptotic signalling via the 
hippo pathway.  
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FIGURE 3.I. CNK1 modulation of Raf-1:MST2 complex formation in a 
concentration-dependent manner. CNK1 modulation of Raf-1:MST2 complex 
formation in a concentration-dependent manner corresponds with the inhibition of MST2 
kinase activity and apoptotic signalling. Results used are derived from data presented as 
follows: The apoptotic inhibition (blue diamond, Figure 3.E, Results are expressed as 
mean +/- SEM, n=3); phosphoMST2 inhibition (dark red triangle, Figure 3.D, Results 
are expressed as mean +/- SEM, n=3); and Raf-1:MST2 complex (gray square, Figure 
3.B.II, Results are expressed as mean +/- SEM, n=6) were plotted as relative signal 
response (fold change) versus the relative CNK1 expression levels. All data were 
normalised to that obtained for control cells. 
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CHAPTER 4 
 
 
The Temporal feature and Selectivity of Signalling by 
CNK1 
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4.1     Introduction 
 
 
 
The ability of a tumour cells to grow exponentially is linked to imbalance between cell 
proliferation and cell apoptosis. Therefore, regulation of programmed cell death or 
apoptosis is usually exploited by tumour cells to get advantage, progress and proliferate. 
Apoptotic evasion represents one of the true hallmarks of cancer and a crucial 
characteristic in the resistance of the most aggressive of human cancers to chemotherapy 
(Hanahan and Weinberg, 2000). Clues on understanding the mechanism integrating 
proliferative and apoptotic signals in cells is therefore crucial.  
 
As discussed in Chapter 1, there are two well-characterised apoptotic pathways. 
Apoptosis on cells can be triggered by various stimuli either externally (Extrinsic 
pathway), e.g. by activation and ligation of cell surface death receptors by specific pro-
apoptotic ligands, or internally (Intrinsic pathway), e.g. by DNA damage as a result of 
defects in DNA repair mechanisms, treatment with cytotoxic drugs or irradiation, loss of 
growth factors, defective cell cycle signalling or other types of severe cell stress 
(Hengartner, 2000; Danial and Korsmeyer, 2004). Hence, chemical stressors such as 
staurosporine and exposure of cells to antibodies against their death receptor CD95/Fas 
induces cell death, and thus are used extensively as a general tool for exploring the 
molecular regulation of apoptosis (Huang et al., 1999; Chae et al., 2000; Belmokhtar et 
al., 2001; Zhang et al., 2004; O’Brien et al., 2005; Mollinedo and Gajate, 2006). 
However, crosstalk between the extrinsic and intrinsic pathways as well as caspase 
dependent and independent mechanisms may exist (Lockshin and Zakeri, 2002; Fulda 
and Debatin, 2006; Elmore, 2007). The pro-apoptotic MST1/2 kinase can be activated 
via caspase and caspase-independent mechanisms in response to cellular apoptotic 
agents such as staurosporine and Fas ligand (Taylor et al., 1996; Lee et al., 1998; Deng 
et al., 2003; O’Neill et al., 2004; Mattalanas et al., 2007; Zhang et al., 2009). In line with 
this, I sought to determine if CNK1 may play a role in mediating Raf-1:MST2 complex 
under these similar severe apoptotic conditions such as CD95/Fas and staurosporine 
induced apoptosis compared to previous chapter wherein challenging the dynamics of 
the complex mediated by CNK1 using growth-withdrawal/ serum-starvation cellular 
stress and to extend the findings in the Fas death receptor signalling pathway. 
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Conversely, activation of receptor tyrosine kinases such as epidermal growth factor 
receptor (EGFR) by mitogenic stimulation leads to activation of Ras-Raf-MEK-
ERK/MAPK pathway (Yarden and Schlessinger, 1987; Yarden and Sliwkowski, 2001). 
Ras activation of Raf kinase directly phosphorylates and activates MEK, which in turn 
directly phosphorylates and activates ERK (Kyriakis et al., 1992; Howe et al., 1992; 
Vojtek et al., 1993; Wellbrock et al., 2004). Consequently, activation of ERK is critical 
for numerous Ras-induced cellular responses including cell growth and proliferation 
(Kolch, 2000).  
 
Interestingly, mitogenic stimulation and oncogenic Ras also dissociate Raf-1 and MST2 
complex. A recent report suggested that in mitogenic conditions, AKT phosphorylates 
MST2 thereby shifting MST2 affinity away from RASSF1A towards Raf-1 (Romano et 
al., 2010). However, in contrast, a study   demonstrated that mitogenic stimulation 
enhanced the interaction of Raf-1 and MST2, including an unexpected positive role for 
MST2 in Raf-1/ERK pathway (Kilili and Kyriakis, 2010). The regulation of Raf-1 and 
MST2 is quite complex and many of the exact mechanisms involved are currently under 
intense investigation. However, in recent years, mechanisms involved in the integration 
between the prosurvival signalling pathway and pro-apoptosis signalling pathways 
implicate scaffold proteins as they have the ability to assemble diverse proteins into 
complexes to foster crosstalk between signalling pathways which provides a mechanism 
to integrate specific responses to diverse array of stimuli in cells (Ebisuya et al., 2005; 
Good et al., 2011). 
 
As CNK1 is a scaffold protein that contains multidomain architecture to enable binding 
of several proteins to its interacting domains, and given the fact that CNK1 binds both 
opposing proto-oncogene Raf-1 and pro-apoptotic MST2 as confirmed by peptide array 
it is therefore conceivable that CNK1 may play a role in the coordination of proliferative 
signals and apoptotic signals that impact on both opposing kinases. Therefore, to gain 
further insight as to the scaffold role of CNK1, I examined the binding dynamics of its 
partners under these different conditions. The data presented here suggests that CNK1 
may potentially provide a level of specificity and temporal regulation by coordinating 
the opposing kinases Raf-1 and MST2 for efficient and appropriate response to a variety 
of stimuli.            
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4.2       Results 
 
 
 
4.2.1 CNK1 is involved in Fas receptor and Staurosporine death 
signalling 
 
 
In the same way as the Raf-1:MST2 complex is modulated by CNK1 upon serum-
starvation induced apoptosis as suggested by the data in Chapter 3, I therefore examined 
whether CNK1’s regulation is extended in response to these apoptotic agents. As stress 
signals and apoptotic stimuli dissociate the Raf-1:MST2 complex and CNK1 binds both 
opposing kinases, I first analyzed the endogenous association of these components 
before and after treatment of cells to determine whether a dynamic change of complexes 
occurs in these conditions. HeLa cells were grown overnight in serum-containing 
medium prior to 16-20 hours of serum-deprived culture medium. After serum starvation, 
cells were stimulated with either Fas antibody or staurosporine for 3-6 hours and 30-120 
minutes, respectively. Cells were lysed and immunoprecipitated with anti-CNK1, 
followed by immunoblotting with anti-MST2, anti-Raf-1 and anti-CNK1. The protein 
expression of Poly (ADP-ribose) polymerase-1 (PARP) was also examined by western 
blotting on the cell lysates. PARP is involved in DNA repair, and is cleaved by caspases 
during the execution phase of the apoptotic program which upon this decisive event 
facilitates cellular disassembly. Hence, it is used extensively as a marker of cells 
undergoing apoptosis (Oliver et al., 1998; Boulares et al., 1999; D’Amours et al., 2001).  
 
Figure 4.A shows that endogenous MST2 and Raf-1 interact with CNK1 consistent with 
previous studies (Rabizadeh et al., 2004; Ziogas et al., 2005). Surprisingly however, 
MST2 started to dissociate at 3 hr Fas stimulation from CNK1 and significantly at 6 hr 
stimulation of cells (first lane) compared to control untreated cells. Conversely, Raf-1 is 
retained in complex with CNK1 (second lane). Consistently, Staurosporine induced 
dissociation of MST2 from CNK1 at 30 min and at 120 min, in contrast to Raf-1 (Figure 
B, lanes 1, 2). MST1/2 are fully activated upon caspase cleavage, or can be initially 
activated independent of caspase upon apoptotic stimuli at an early time point of 
treatment prior to cleavage for further full activation (Lee et al., 2001; O’Neill et al., 
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2005; Mattalanas et al., 2007). Interestingly, these events seem to be observable prior to 
the detection of cleaved PARP in these cells. At 2 hr Staurosporine treated cells, MST2 
has started to dissociate, while the intact form of PARP is still observable. Subsequently 
the cells treated with Fas at 6 hr, showed a significant decrease in MST2’s interaction 
with CNK1, along with a concomitant appearance of the 89 kDa cleaved fragment of 
PARP compared to untreated cells. Although PARP cleavage was not observed in 
Staurosporine treated cells probably due to shorter exposure time, a clear dissociation of 
MST2 was evident compared to untreated cells. These data indicate that CNK1 
preassembles a CNK1/MST2/Raf-1 signalling module in non-stimulated cells. Taken 
together, these data suggest that CNK1 may also possibly facilitate the release of pro-
apoptotic MST2 kinase in response to a potent apoptotic stimulus such as Fas antibody 
for activation, while restraining Raf-1 in the complex. 
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Figure 4.A and 4.B. CNK1 is involved in Fas receptor and Staurosporine death   
signalling 
 
A. 
 
B. 
 
 
Figure 4.A and 4.B. CNK1 is involved in Fas and Staurosporine death signalling. 
After 16-20 hr serum-starvation, HeLa cells were untreated or treated with either Fas 
agonistic antibody CH-11 at 100 ng/ml for 3 hr and 6 hr or Staurosporine at 1μM for 30 
and 120 min. Cells were lysed and immunoprecipitated (IP) with Anti-CNK1. 
Endogenous MST2, RASSF1A and Raf-1 co-immunoprecipitated with CNK1 from cells 
treated or untreated with apoptotic agents were analysed by western blotting with the 
indicated antibodies. Cells lysates were examined for the intact and cleaved forms of 
Poly (ADP-ribose) polymerase-1 (PARP) using anti-PARP. Tubulin immunoblot was 
used as a loading control. Full-length PARP and the cleaved fragment are indicated with 
arrows. Western blot image is a representative of two independent experiments. 
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4.2.2 CNK1 delays Fas-induced disruption of MST2: Raf-1  
            interaction. 
 
 
Reversible protein-protein interactions are common in most biochemical pathways in 
cells. Indeed, the cellular decision to undergo apoptosis is determined by the integration 
of multiple survival and death signalling proteins (Degterev et al., 2003; Andersen et al., 
2005; Guicciardi and Gores, 2009). Most often, scaffold proteins are dependent on the 
integration and formation of signalling components to carry out such vital cellular 
functions (Houtman et al., 2005; Alexa et al., 2010). 
 
As Fas stimulation of cells suggests a time-dependent disruption of MST2 from the 
CNK1/Raf-1 complex (Figure 4.A), through protein–protein interactions, CNK1 may be 
able to rescue the dismantling of the complex by increasing local concentration of Raf-1 
and preventing release of MST2. To determine this, first a time-course experiment 
examining the dissociation of the Raf-1:MST2 complex in cells treated with an agonist 
Fas antibody at different time points (0, 2, 4, 6 hr) but transfected with an intermediate 
CNK1 plasmid concentration (0.2 μg DNA)  that promotes the highest interaction of 
Raf-1 and MST2 was performed. Hela cells were then transfected with 0.2 μg of Myc-
CNK1 plasmid or control empty vector as before. Following serum starvation, cells were 
treated with an agonist Fas antibody at the indicated time and reciprocal 
immunoprecipitations of Raf-1 and MST2 proteins were analysed by western blot to 
investigate the dynamic change of the complex when exposed to Fas mediated by 
CNK1. Figure 4.C shows that in untransfected control cells, dissociation of Raf-1 and 
MST2 is already evident at 2 hr Fas stimulation and persists up to 6 hr. Both Raf-1 (first 
lane) and MST2 (third lane) immunoprecipitates blotted with associated antibodies 
exhibited similar results. However, cells transfected with Myc-CNK1 plasmid (0.2 μg) 
display an elevated Raf-1 and MST2 interaction at 2-4 hr time point, and this complex 
dissipates by 6 hr Fas stimulation. These findings indicate that at a definite exposure 
time of cells to apoptotic stimuli, CNK1 at a certain expression level may rescue the Fas-
induced disruption of Raf-1:MST2 complex.  
  105
 
 
 
Figure 4.C. CNK1 delays Fas-induced disruption of Raf-1:MST2 interaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.C. CNK1 delay Fas-induced disruption of Raf-1:MST2 interaction. After 
16 hr serum-starvation of transiently transfected cells either with 0.2 μg Myc-CNK1 
expression plasmids or empty vector, cells were treated with 100 ng/ml Fas agonistic 
antibody CH-11 at indicated time points. Cells were lysed and reciprocal 
immunoprecipitation of Raf-1 and MST2 were analysed by western blotting with 
indicated antibodies. Extracts were monitored for CNK1 expression with ani-CNK1 and 
tubulin for loading control. Western blot image is a representative of two independent 
experiments. 
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4.2.3 Levels of CNK1 affect MST2 phosphorylation in Fas-
stimulated cells. 
 
 
Raf-1 can interfere with Fas signalling by binding and inhibiting MST2 activation 
(O’Neill et al., 2004; Mattalanas et al., 2007). In light of the findings that CNK1 may 
delay the Fas-mediated disruption of Raf-1:MST2 hence may also delay apoptosis, I 
next wanted to extend these studies and determine whether CNK1 can still mediate the 
MST2: Raf-1 complex in a concentration-dependent manner during Fas death receptor 
signalling. I therefore carried out overexpression experiments similar to those in Chapter 
3. As before, HeLa cells were transiently transfected with control empty vector or Myc-
tagged CNK1 expression plasmids in increasing amounts (0-1.5 μg Myc-CNK1 DNA). 
Following serum starvation, cells were treated with Fas antibody for 4 hr, lysed and 
MST2 proteins were immunoprecipitated. Endogenous Raf-1 proteins that co-
immunoprecipitated with MST2 were analysed by western blotting. As MST2 is 
activated via apoptotic agents such as Fas stimulation, phosphorylation status of MST2 
was examined using anti-phophoMST2 antibody.  
 
The CNK1-mediated interaction of Raf-1 and MST2 shows a different pattern when 
cells are treated with Fas at 4 hr stimulation in comparison to serum-starvation studies. 
Figure 4.D shows that in cells transfected with intermediate CNK1 plasmid 
concentration (0.05-0.25 μg Myc-CNK1), the Raf-1 and MST2 interaction compared to 
control (empty vector) was only slightly elevated. However, in cells transfected at higher 
concentrations (1.5 μg Myc-CNK1 DNA), the Raf-1:MST2 complex was significantly 
disrupted consistent with serum-starvation studies when cells are transfected with high 
CNK1 plasmid concentration. This observation also correlated to the phosphorylation 
status of MST2, i.e. in cells transfected at intermediate CNK1 plasmid concentration, the 
phosphorylation of MST2 was decreased while at high concentrations it was enhanced 
(second lane). Cell lysates were also probed with Anti-CNK1 to monitor CNK1 
expression levels (fourth lane) and tubulin for loading control (last lane).  Although, the 
results suggest that CNK1 may rescue cells due to inhibition of MST2 phosphorylation 
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in a concentration dependent manner under a potent apoptotic stimulus, whether the pool 
of MST2 sequestered by CNK1 to interact with Raf-1 is sufficient to represent the total 
amount of MST2 activated to induce apoptosis in these cells needs to be clarified by an 
apoptosis assay. Nevertheless, the results suggest that under a severe apoptotic stimulus, 
CNK1-mediated assembly of an apoptotic Raf-1:MST2 inhibitory complex may possibly 
delay or rescue cells from apoptosis via Fas stimulation by its ability to recruit inhibitory 
Raf-1 pools and simultaneously sequester and protect MST2 from phosphorylation 
which is crucial for its activation in a concentration dependent manner.  
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Figure 4.D. Levels of CNK1 affect MST2 phosphorylation in Fas stimulated cells 
 
 
 
 
 
 
 
 
Figure 4.D. Levels of CNK1 affect MST2 phosphorylation in Fas stimulated cells. 
Cells were transfected with empty vector or increasing amounts of Myc-CNK1 plasmid 
as indicated. Following serum starvation, Cells were treated with 100 ng/ml Fas 
agonistic antibody CH-11 for 4 hours. Immunoprecipitated MST2 proteins were 
analysed by western blotting. Phosphorylation level of MST2 was determined using anti-
phosphoMST2.  Cell lysates were probed with anti-CNK1 to verify CNK1 expression 
and anti-tubulin for loading control. Western blot image is a representative of two 
independent experiments. 
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4.2.4   CNK1 reassembles its components in response to     
              mitogenic stimulus   
              
 
Raf-1 kinase relays the signals from EGFR-Ras to MEK and ERK kinases to confer 
different biological consequences which are regulated by protein-protein interactions, 
complex phosphorylation events, and adding to this complexity, implicated to be 
regulated by a growing number of scaffold proteins (Anselmo et al., 2002; Wellbrock et 
al., 2004; Kolch, 2005). Formation of appropriate complexes by scaffold proteins plays 
an important part in the specificity of the cell response to various stimuli (Vondriska et 
al., 2004; Marinissen and Gutkind, 2005). In line with this idea, I therefore examined if 
the Raf-1:MST2 complex mediated by CNK1 responds to mitogenic stimuli as Raf-1, a 
component of the CNK1 complex, is activated upon mitogenic epidermal growth factor 
(EGF) stimulus. I also investigated whether this complex is involved in the ERK/MAPK 
signalling pathway. EGF is a ligand that binds and activates EGFR, and has a potent 
growth-promoting effects in cells, stimulating cellular proliferation and differentiation; 
hence EGFR is usually hypermutated in cancer (Yarden and Sliwkowski, 2001; 
Schlessinger, 2002; Breuhahn et al., 2006). 
 
Consistent with previous studies (Rabizadeh et al., 2004; Ziogas et al., 2005) and data 
presented here (Figure 4.A and 4.B), endogenous Raf-1 and MST2 bind to CNK1 in 
Hela cells, as shown in Figure 4.E.  Surprisingly, analysis of CNK1 immunoprecipitates 
from cells treated with EGF showed that in contrast to Fas stimulation, MST2 is retained 
in complex with CNK1, while Raf-1 is dissociated from CNK1 in a time-dependent 
manner (lanes 1 and 2). This observation is in parallel with the analysis of MST2 
immunoprecipitates of cells treated with EGF, i.e. Raf-1 dissociated from MST2 
similarly in a time-dependent manner (lane 4). Because the change in CNK1/MST2/Raf-
1 complex may be a result of activated Raf-1, cells lysates were examined for the 
activation of direct downstream kinases of Raf-1. As expected, in cells treated with EGF 
that dissociated Raf-1 from CNK1/MST2 complex, resulted in the activation of MEK 
and ERK as revealed by using anti-phosphorylation antibodies (lanes 6 and 7). The study 
was extended using the growth promoting supplement foetal bovine serum (10% FBS) 
over different periods of time (30 and 120 min). Consistently, compared to untreated 
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cells Raf-1 readily dissociated from the CNK1/MST2 complex. Raf-1 
immunoprecipitates also confirmed the disruption of the Raf-1:MST2 complex in a time-
dependent manner upon FBS stimulation of cells. Raf-1 dephosphorylation at S259 of 
Raf-1 immunoprecipitates suggests activation of Raf-1 kinase, which also confirms 
direct downstream ERK activity that was observed upon mitogenic stimuli of cells. 
Consistently, cells treated with insulin growth factor (IGF) and platelet-derived growth 
factor (PDGF) exhibit similar behaviour (Figure 4.G and 4.H) to EGF and 10% FBS in 
dissociating Raf-1 from the CNK1/MST2 complex, albeit there is difference in the 
duration of treatment. Interestingly, in cells treated with either of the mitogens, wherein 
phospho-ERK is transiently enhanced, Raf-1 dissociates from the CNK1/MST2 complex 
more readily. However, at longer and sustained stimulation wherein phosphor-ERK is 
back at basal levels, Raf-1 seems to be retained back to the complex. This observation is 
especially pronounced in cells treated with the growth factor PDGF. This observation 
may suggest that CNK1 may respond differently, depending on the type and duration of 
mitogenic stimulants.  
 
The finding of the Raf-1:MST2 complex dissociation promoted by mitogenic stimuli 
presented here confirms previously observed reports (O’Neill et al., 2004; Romano et al., 
2004). However, it was shown for the first time in this chapter that Raf-1 and MST2 are 
preassembled with CNK1 prior to a variety of mitogenic stimuli. Taken together, the 
data suggest that MAPK signal-transduction pathway may influence the ability of CNK1 
to reassemble its components, i.e. Raf-1 and MST2 in response to the duration and type-
specific mitogenic stimulation. 
 
Preliminary studies of ectopic overexpression of CNK1 at different concentrations 
suggests a possible EGF duration-dependent effects on the Raf-1:MST2 complex (data 
not shown), however further confirmatory experiments need to be performed to get 
conclusive data, as I have I focused my attention on mapping the interaction domains of 
CNK1. 
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Figure 4.E and 4.F. CNK1 reassembles its components in response to mitogenic 
stimulus 
 
 
E. 
 
 
 
F. 
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G. 
 
H. 
 
 
Figure 4.E and 4.F. CNK1 reassembles its components in response to mitogenic 
stimulus. (4.E) Following serum starvation, HeLa cells were either untreated or treated 
with 200 ng/ml of EGF for the indicated durations. CNK1 immunoprecipitates were 
analysed for endogenous co-immunoprecipitated MST2 and Raf-1 by immunoblot with 
indicated antibodies. MST2 immunoprecipitates were also analysed for co-
immunoprecipitated Raf-1. MEK and ERK activity were examined using anti-phospho 
antobodies. (4.F) Following serum starvation of HeLa cells, cells were untreated or 
treated with 10% FBS at indicated durations. Endogenous Raf-1 and MST2 co-
precipitated with CNK1 was analysed by immunoblot. Raf-1 immunoprecipitates were 
also analysed for co-immunoprecipitated MST2, as well as its activity using anti-
phospho S259 antibody. Cell lysates were monitored for ERK/MAPK activity. (4.G, 
4.H) Similar to above, but serum starved cells were untreated or treated with either 100 
ng/ml of IGF or 20 ng/ml of PDGF, respectively. Endogenous Raf-1 and MST2 co-
precipitated with CNK1 were analysed by immunoblot. Cell lysates were monitored for 
ERK/MAPK activity. Western blot image (Figure 4.E-4.H) is a representative of two 
independent experiments. 
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4.2.5 Mapping the interaction domains of CNK1 
 
 
Because regulated protein–protein interactions play an important role in the transmission 
of cellular signals, molecular scaffolds have emerged as key modulators of the signalling 
process (Kolch, 2005). Therefore, to gain further insight as to the role of the CNK1 
protein in signal transduction, in particular its role in the regulation of its associated 
proteins Raf-1 and MST2, a peptide array approach was used to map and determine the 
binding sites of these proteins to the CNK1 scaffold. 
 
As discussed in Chapter 1, CNK proteins are evolutionarily conserved scaffold proteins 
crucial to a variety of signalling pathways. It is considered a scaffold protein as its 
architecture contains several interaction domains (Figure 4.J). The N-terminal part of 
CNK1 includes a sterile alpha motif (SAM), a conserved region in CNK (CRIC) and a 
PSD-95/DLG-1/ZO-1 (PDZ) domain. The C-terminal portion of CNK consists of a 
pleckstrin homology (PH) domain and polyproline sequences. CNK1 also contains a 
potential coiled-coil region, a unique proline-rich region that spans about 90 amino acids 
sequences and a conserved region among chordate (CRAC) domain that are common to 
mammalian CNK isoforms but are absent in Drosophila and C. Elegans (Claperon and 
Therrien, 2007; Fritz and Radziwill; 2005)  
 
As indicated in this chapter, Raf-1, MST2 and RASSF1A were indentified to interact 
with CNK1 using two-hybrid, pull-down and co-immunoprecipitation methods 
(Rabizadeh et al., 2004; Ziogas et al., 2005). In this study, I explored this interaction 
further by using peptide array screening analysis that permits highly parallel synthesis of 
huge numbers of peptides spotted on nitrocellulose. Peptide library formats by use of 
SPOT-peptide arrays have been successfully used in carrying-out general protein–
protein/peptide interaction studies including mapping and analysis of linear binding sites 
of several receptors, chaperones, cell-skeleton proteins and signalling molecules (Frank, 
2002; Hilpert et al., 2007; Wu and Li, 2009). 
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To do this, synthesised libraries of overlapping 25-mer peptides, each shifted by five 
amino acids, spanning the complete sequence of CNK1 was immobilised on cellulose 
membranes and probed with [35S] Raf-1, MST2 and RASSF1A labelled proteins using a 
coupled in vitro transcription/translation kit as described in Chapter 2 Materials and 
Methods. The radioactive signals on arrays were autoradiographed using a 
phosphoimager. 
 
As shown in Figure 4.I, the possible binding regions of Raf-1, MST2 and RASSF1A 
within CNK1 are categorised as strong and medium, and boxed as yellow and red 
respectively. A detailed analysis of the positive regions on the array indicates that the 
three proteins involve several sites of contact; dark spots signified positive interactions 
(Figure 4.J). In vitro co-overexpression of both tagged-Raf-1 and truncated CNK1 was 
shown to interact. In particular, it was shown that full-length CNK1 was able to bind 
Raf-1, including its C-terminal region (starting at PDZ domain) but not its N-terminal 
region (SAM and CRIC region). Therefore, it was suggested that Raf-1 binds to the C-
terminal of CNK1 (Rabizadeh et al., 2004). Consistently, the results indicated that Raf-1 
binds mostly on residues comprising the C-terminal that contains the proline-rich region 
and PH domain with strong affinity (Figure 4.J, first panel). However, the findings 
indicate that Raf-1 also binds to CNK1 at several sites in the amino terminal region 
particularly in the SAM to PDZ domain region. 
 
MST1/2 kinases were found to bind CNK1 through their SARAH domain located on 
their C-terminal. However, no previous studies reported on the mapping of their binding 
regions on CNK1 (Rabizadeh et al., 2004). Herein, peptide arrays indicate that MST2 
binds to CNK1 mostly at residues 254-463 that contains regions of proline-rich region 
and PH domain showing strong affinity (Figure 4.J, second panel). Also, a few regions at 
coiled-coil regions and PDZ domains showed possible binding sites.  
 
Similar to MST2, RASSF1A was previously shown to bind to CNK1 through its 
SARAH domain on its C-terminal. RASSF1A binds mostly on CNK1’s amino-terminal 
region, 1-282 residues of the N-terminal and 77-279 that contains the CRIC and PDZ 
binds well to RASSF1A, while residues 199-279 exhibited modest binding. 
Interestingly, residues 279-713 which lacks the PDZ domain did not bind to RASSF1A. 
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Therefore, it was suggested that PDZ and CRIC was required for binding of CNK1 to 
RASSF1A (Rabizadeh et al., 2004). Consistent with this previous report, positive 
binding signals showed at CRIC and PDZ domains of CNK1 (Figure 4.J, third panel). 
However, peptide screening suggests that RASSF1A binds a wider region that comprises 
CRIC, PDZ and the PH domain and a few other strong residues at the C-terminal regions 
particularly at the coiled-coil regions. 
  
Interestingly, further analysis of the possible binding sites of Raf-1, MST2 and 
RASSF1A indicates overlapping binding residues on CNK1. In particular, RASSF1A 
and Raf-1 had 10 similar binding residues to CNK1 either categorised as medium or 
strong affinity mostly on residues that encompass the PDZ, proline-rich, coiled-coil and 
PDZ domains. However, Raf-1 has 9 unique binding residues found in the SAM, CRIC 
and PH domains of CNK1. RASSF1A has 5 unique binding residues found at CRIC, 
proline-rich and at the C-terminal end of CNK1. Intriguingly, MST2 alone has no unique 
binding residue as most of it is shared with RASSF1A and all three proteins share 6 
binding residues that reside mostly on PDZ (2 residues), Proline-rich (1 residue), PH (1 
residue) and coiled-coil regions (2 residues).   
 
As described in Chapter 1, interaction domains are crucial for the specificity of signal 
transduction downstream of cell-surface receptors and serve as binding modules that 
control many aspects of cellular mechanism and spatial organization of different 
molecules. Importantly, scaffold proteins utilize their several protein-protein interaction 
domains to recruit proteins and to mediate assembly of components for signalling 
(Pawson and Nash, 2000). In line with this, the finding from this peptide array screening 
study is consistent with the modular architecture of CNK1, as most of the binding 
residues exhibited by its client proteins lie mostly on its interacting domains.  
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Figure 4.I. Mapping the interaction domains of CNK1 
 
 
 
 
 
 
 
Figure 4.I. Mapping the interaction domains of CNK1. Nitrocellulose membranes 
were spotted with synthetic 25-mer peptides offset by 5 amino acids representing the 
whole CNK1 sequences. CNK1 on peptide array were probed with [35S] Raf-1, MST2 
and RASSF1A labelled proteins using a coupled in vitro transcription/translation kit as 
described in Chapter 2 Materials and Methods. The radioactive signals on arrays were 
autoradiographed using a phosphoimager. Positive binding sites were categorised as 
strong (yellow boxes) or medium (red boxes). Peptide array blot image is a 
representative of two independent experiments. 
 
. 
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Figure 4.J. Analysis of binding sites from the peptide array 
 
 
 
 
 
Figure 4.J. Analysis of binding sites from the peptide array. CNK1 protein with 
protein length of 713 amino acids is schematically shown with the following domains 
and motifs colour coded as indicated. Regions indicated are as follows: 7-70 (SAM 
domain), 78-164 (CRIC domain), 196-285 (PDZ domain), 285-378 (Pro-rich), 403-503 
(PH domain), 616-646 (Coiled-coil). Raf-1, MST2 and RASSF1A used to probe the 
arrays are bracketed, and the mapped sites of interaction are shown as amino acid 
numbers and boxed according to binding affinity as indicated by yellow boxes (strong 
affinity) or red boxes (medium affinity). Indicated above the schematic are the binding 
sites of Raf-1, MST2 and RASSF1A found in the present study. Interaction sites 
identified prior to the present study are indicated below. 
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4.2.6 A short motif within CNK1 is necessary in mediating Raf-
1:MST2 complex 
             
             
To further characterise the binding sites mapped from the peptide array screening of 
Raf-1 and MST2 on CNK1, I therefore set out to generate truncated forms and mutants 
based on the screening results using site-directed mutagenesis as described in Chapter 2 
Materials and Methods. Remarkably, further analysis of the peptide array data revealed a 
common binding site of Raf-1 and MST2 that stretches along the proline-rich region of 
CNK1 that exhibited a very strong signal. This was identified as the short motif Arg-
Lys-Lys-Ser-Lys (RKKSK) that covers the peptide sequence 374-378, as schematically 
represented in Figure 4.K.I. This suggests that the short motif region that spans between 
the proline-rich and PH domain of CNK1 maybe essential for CNK1’s function in 
mediating Raf-1 and MST2 complex.  
 
Unfortunately, inserted tags designed to generate HA-tagged truncated and mutant forms 
were not verified by sequencing. Because of this technical problem and due to time 
constraints, I therefore decided to perform an analysis of mutants generated prior to 
insertion of tags and used to assess the effect on the Raf-1:MST2 complex. 
 
Database searches of CNK1 in the region that spans the short peptide sequence 
(RKKSK) reveal that the Serine at this residue is a highly predicted Serine 
phosphorylation site (predicted by Scansite motif Scan; http://scansite.mit.edu/motifscan 
or NetPhos2.0; http://www.cbs.dtu.dk/services/NetPhos), and interestingly is also 
predicted as a 14-3-3 binding site. Therefore, site-specific mutagenesis at the Serine 
residue of the identified short RKKSK motif were generated (i.e. S377A and S377D) 
and tested for their ability to mediate Raf-1 and MST2 interaction in cells. 
 
Plasmids encoding wild-type CNK1 and the indicated mutants were transiently 
transfected at increasing amounts into Hela cells i.e. wild-type CNK1 at 0.2, 05, 1.5 μg, 
and CNK1 mutants at 0.2 and 1.5 μg of plasmid DNA. Following serum starvation, cells 
were lysed and Raf-1 immunoprecipitates were examined for co-immunoprecipitated 
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MST2 proteins by immunobloting. As shown in Figure 4.K.II, whereas cells transfected 
with wild type CNK1 exhibit the usual bell-shaped effect by mediating the interaction of 
Raf-1 and MST2 in a concentration-dependent manner, CNK1 mutants exhibited a 
different interaction pattern of Raf-1 and MST2 interaction. Substitution of S377 with 
Alanine (S377A) mutants showed no change of Raf-1 and MST2 interaction at either 
intermediate concentration or at high concentrations compared to the wild type control. 
Thus, replacement of serine 377 of CNK1 with Alanine abrogates scaffold function 
potentially by changing the binding affinity towards Raf-1 and MST2 as they may no 
longer be recruited to CNK1. Although, CNK1 transfection protocol has been 
demonstrated to be highly efficient it should be noted that expression of CNK1 in this 
western blot experiments was not monitored. Interestingly, substitution of S377 with 
Aspartic Acid (S377D) mutants showed only an increased interaction of Raf-1 and 
MST2 at higher concentrations therefore no longer manifest the bell-shaped scaffold 
effect of mediating Raf-1 and MST2 of wild-type CNK1. A clearer interpretation of this 
result requires determination of independent binding capacity of these mutants 
independently of Raf-1 and MST2 by pull-down immunoprecitation using tagged-CNK1 
mutant constructs, however these findings suggests that the short RKKSK motif region 
of CNK1 may play an important role in the scaffolding function in mediating Raf-1 and 
MST2 interaction.  
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Figure 4.K. A short motif within CNK1 is necessary in mediating the Raf-1:MST2    
                     complex 
 
 
I. 
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II. 
 
 
 
 
 
Figure 4.K. A short motif within CNK1 is necessary in mediating the Raf-1:MST2   
complex. (I) A Schematic of CNK1 showing its multi-domain structure and motifs 
colour coded as indicated, and locations of CNK1 mutations studied. Amino acid 
sequence of sequential 25-mer CNK1 peptides offset by 5 amino acids with indicated 
peptide number identified from the short motif. Positive strong signals on the arrays 
probed with Raf-1, MST2 and RASSF1A from Figure 4.I are compared to show the 
common binding motif. (II) Analysis of CNK1 mutants and wild-type CNK1 in HeLa 
cells under serum-starved conditions. Cells were transfected with CNK1 mutants or 
wild-type CNK at indicated concentrations. Following serum starvation, lysates were 
subjected to immunoprecipitation and Raf-1 immunoprecipitates were analysed by 
immunobloting with indicated antibodies. Equal loadings were confirmed using 
antibodies against tubulin. Western blot image is a representative of two independent 
experiments. 
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4.3 Discussion 
 
 
 
CNK1 is involved in Fas receptor and Staurosporine death 
signalling 
 
In Chapter 3, the results presented indicate a scaffold role of CNK1 by mediating the 
inhibitory Raf-1:MST2 complex in a ‘bell-shaped’ concentration-dependent manner that 
results in either inhibiting or promoting a serum-starvation cellular stress-induced MST2 
activation and MST2/Hippo apoptosis of cells, typical manifestations of a scaffold 
protein.  
 
Scaffold proteins are also believed to promote specificity by their ability of binding and 
coordinating simultaneously to multiple components of a signalling pathway. This 
specificity is achieved by several mechanisms, including temporal and spatial control of 
signalling components. In particular, it has been proposed that scaffolds may assemble 
specific bound components into pathway-dedicated signalling molecules in response to 
stimuli and prevent components from straying away or protecting them from other 
signalling intrusions  (Murphy and Blenis, 2006; Brown and Sacks, 2009). 
 
The results presented here extended the scaffold functions of CNK1 in the regulation of 
Raf-1:MST2 complex. In this chapter, I have shown that CNK1 may be involved in Fas 
death receptor apoptotic signalling through regulation of the tumour suppressor MST2 
kinase. First, no previous characterization of the interaction between endogenous MST2, 
Raf-1 and CNK1 has been reported. Here, it was revealed that in quiescent cells MST2, 
Raf-1 and CNK1 are preassembled. However, upon Fas stimulation, MST2 dissociates 
from this trimeric complex (Figure 4.A). These data demonstrate and further support 
why MST2 and Raf-1 interaction are enhanced in serum-starved cells and dissociate 
when MST2 is activated (O’Neill et al., 2004), as MST2 is sequestered by CNK1 and 
links to Raf-1, hence restrains from activation of inevitable loss of growth factors and as 
  123
a consequence of this prolonged cellular stress, MST2 is released from the CNK1/Raf-1 
complex to be activated, and can therefore promote apoptosis of cells. 
 
  
CNK1 delays Fas-induced disruption of MST2: Raf-1 interaction 
 
While Fas agonist antibody or Staurosporine renders a more potent apoptotic stimulus, 
dissociation of MST2 from CNK1/Raf was relatively rapid, occurring within hours from 
the start of stimulation (Figure 4.A and 4.B). This finding therefore suggests a time-
dependent dissociation of MST2 from the Raf-1/CNK1 complex. To exploit a possible 
temporal scaffold function of CNK1, an optimal concentration level that promotes 
reassembly of Raf-1 and MST2 was used to test this possibility. Indeed, the findings 
revealed that CNK1 may rescue the release and impending activation of MST2 in a time-
dependent manner (Figure 4.C and 4.D). MST2 depends on the phosphorylation of 
Thr180 for kinase activity, which occurs prior to caspase cleavage (Graves et al., 2001; 
O’Neill et al., 2004). Phosphorylation of full-length MST1/2 can be reversed by protein 
phosphatases such as PP2A, unlike the cleaved form that translocates to the nucleus 
where it promotes chromatin condensation during apoptosis (Ura et al., 2001; Deng et 
al., 2003; O’Neill et al., 2004). Curiously, in a recent mass spectrometry analysis, CNK1 
complexes contained peptides from three subunits of the serine/threonine phosphatase 
PP2A, implicating PP2A as a potential regulator of CNK phosphorylation (Kim et al., 
2010). It is therefore plausible that CNK1 at an optimal expression level may provide 
protein phosphatases such as PP2A by recruiting them to the complex, along with the 
recruitment of inhibitory Raf-1 function in close proximity to sequester, inactivate and 
protect MST2 from further activation. Taken together, the time-course Fas stimulation 
study of the Raf-1:MST2 complex under the regulation of dose-dependent 
overexpression of CNK1 suggests that CNK1 may manifest a temporal regulation of the 
Fas death receptor signalling by mediating the phosphorylation and activation of MST2, 
through linking of Raf-1 and possibly phosphatases to form an inhibitory complex that 
may delay or restrict Fas death receptor apoptotic signalling in cells.  
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Levels of CNK1 affect MST2 phosphorylation in Fas-stimulated 
cells. 
 
MST2 is also activated independently of caspase cleavage by RASSF1A (Mattalanas et 
al., 2007; Romano et al., 2010; Guo et al., 2011). RASSF1A phosphorylation of MST2 
is specific to full length MST2 as the caspase-cleaved truncated forms do not contain the 
SARAH domains at the C-terminal of the kinase which are required for RASSF1A 
binding ((Mattalanas et al., 2007). Intriguingly, the SARAH domain that is present on 
both proteins binds to the C-terminal of CNK1 (Rabizadeh et al., 2004) which suggests 
that CNK1-bound MST2 may also be specific to the full length MST2. Moreover, 
autophosphorylation of MST2 is dependent on abundance on its concentration which 
appears to have important regulatory significance (Deng et al., 2003). It can be argued 
that CNK1 may promote such a mechanism, as one function of a scaffold protein is to 
enhance local concentration of its client proteins and enhance interaction between 
signalling molecules (Shaw and Filbert, 2009). Incidentally,  in the LoVo human colon 
carcinoma line, the abundance of CNK1 in the MST1 (close homologue of MST2)  
immunoprecipitate is greatly increased after overnight serum withdrawal, as well as 
CNK1 and RASSF1A in 293 cells (Rabizadeh et al., 2004). Coincidentally, as reported 
here, MST2, Raf-1 and CNK1 are preassembled in serum-starved cells further 
supporting this finding. 
 
Upon apoptotic stimulation, RASSF1A activates and releases MST2 away from Raf-1 
and promotes its association to its substrate LATS1 to signal downstream Hippo 
signalling to promote apoptosis (Mattalanas et al., 2007). More recently, it was reported 
that RASSF1A activates MST1/2 by preventing dephosphorylation of its activating 
Thr180 site by protein phosphatase PP2A (Guo et al., 2011). Interestingly, it was also 
reported by the same group that MST2 and RASSF1A are preassembled in unstimulated 
cells. In line with these findings and together with the data presented here, it is 
conceivable that CNK1 scaffold protein may play a central role in regulating this 
mechanism, given the fact that CNK1 binds both RASSF1A and MST2, and has been 
demonstrated to promote apoptosis when co-expressed with RASSF1A and MST1/2 
(Rabizadeh et al., 2004). In addition, CNK1/RASSF1A/MST2 complexes are 
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preassembled prior to apoptotic stimulus as supported by previous reports (Rabizadeh et 
al., 2004; Guo et al., 2011).  
 
Consistent with these findings, it is therefore tempting to speculate the following model 
that the recruitment of MST2 by RASSF1A to promote MST2 phosphorylation, binding 
to its substrate LATS1 and inducing apoptosis may be regulated by CNK1. The scaffold 
protein CNK1 preassembles a CNK1/MST2/RASSF1A sequestered in an inactive 
complex in quiescent cells, in response to an incoming apoptotic stimulus, CNK1 may 
then facilitate the activation of MST2 by RASSF1A and release of both proteins to 
interact that results in the formation of an MST2/LATS1 apoptotic signalling complex. 
 
Nevertheless, the mechanistic steps by which the CNK1/RASSF1A/MST2 complex 
facilitates a tumour suppressive function and the coordination of an inhibitory Raf-1 into 
the complex in response to apoptotic stimuli remain unclear. Likewise, the dynamic 
change that occurs in the CNK1/MST2/Raf-1 complex in response to mitogenic stimuli 
is still elusive. Although it is not surprising as Raf-1 regulation is highly complex and 
multifaceted. However, the findings presented here may provide a foundation and a 
direction in investigating the mechanism of CNK1, in particular the regulation of MST2 
and Raf-1 involvement in MAPK signalling.   
 
 
CNK1 reassembles its components in response to mitogenic 
stimulus   
 
MST2 is activated upon stress and apoptotic stimuli leading to dissociation of Raf-
1:MST2 complex (Mattalanas et al., 2007). On the other hand, another study has shown 
that oncogenic Ras and mitogens also disrupt Raf-1:MST2 complex without the 
activation of MST2 (O’Neill et al., 2004). Immunoprecipitation of CNK1 and analysis of 
co-precipitated Raf-1 and MST2 here may shed light on to this discrepancy. The 
findings indicate that prior to mitogenic or apoptotic stimulation, CNK1 preassembles a 
CNK1/MST2/Raf-1 complex. Upon cellular stimulation, Raf-1 and MST2 dissociates, 
and whichever signalling molecule may require activation will be released. 
Alternatively, whichever signalling molecule is not required for signalling is sequestered 
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to CNK1, dependent on the subsequent specific stimulus. Thus, the dissociation Raf-1 
and MST2 in response of either apoptotic or mitogenic stimulation is observed. 
 
However, a recent study by Romano et al. (2010) has suggested an alternative 
explanation of this conundrum. Because AKT can be activated via activated Ras or by 
mitogenic stimulation, the authors suggested that AKT phosphorylation of MST2 at 
T117/T384, which are different from the activating site, may protect MST2 activation 
during growth factor stimulation by maintaining the dissociation of MST2 from 
RASSF1A and binding of MST2 to Raf-1 in cancer cells. Interestingly, in a recent report 
CNK1 was found to be critical for the activation of the downstream PI3/AKT cascade 
upon IGF stimulation (Lim et al., 2010). Moreover, CNK1 interacts directly with AKT 
in inhibiting the activation and cytoplasmic sequestration of pro-apoptotic FoxO 
transcription factors (Fritz et al., 2010). In line with this, MST1/2 promotes apoptosis by 
activating FoxO in response to oxidative stress (Lehtinen et al, 2006). As AKT binds to 
the C-terminal and N-terminal of CNK1, it is plausible that CNK1 recruitment of Raf-1 
in cooperation with AKT phosphorylation of MST2 induces binding with Raf-1 thereby 
protecting MST2 and/ or over-all AKT-dependent inhibition of MST2-mediated 
apoptosis which may further underscore the role of CNK1 in mediating MST2. 
 
However, CNK1-mediated protection of MST2 activation may well be dependent on the 
ability of CNK1 to recruit Raf-1 and MST2 at an optimal stoichiometric level under 
apoptotic conditions. In contrast, whether CNK1 is dependent on recruitment of MST2 
and Raf-1 to influence Raf-1 kinase activation under mitogenic conditions, and if MST2 
has a reciprocal role in Raf-1 regulation remains to be determined. As alluded to earlier, 
preliminary results indicate that ectopic overexpression of CNK1 at different 
concentrations suggest a possible EGF duration-dependent effect on the Raf-1:MST2 
complex (data not shown), however further confirmatory experiments need to be 
performed to get a conclusive data as I instead focused my attention on mapping the 
interaction domains of CNK1 due to time constraints. Interestingly, a recent report 
demonstrated an unexpected positive role for MST2 in the Raf-1/ERK pathway (Kilili 
and Kyriakis, 2010). The authors demonstrated that MST2 regulates Raf-1 activation at 
least in part through the maintenance of optimal expression levels of PP2A-C which in 
turn reduces Raf-1 Ser-259 inhibitory phosphorylation. As they could not detect 
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endogenous PP2A-C or PP2A in endogenous MST2 or Raf-1 immunoprecipitates, they 
therefore suggested that if an endogenous complex exists to stabilize PP2A, the 
stoichiometry of the endogenous complex may be low, or the complex may be unstable. 
It is tempting to speculate that this is consistent with the suggested model of CNK1 i.e. 
the possibility of recruiting PP2A to inhibit MST2 or in this case under mitogenic 
conditions for Raf-1 kinase regulation, as CNK1 is a possible regulator of protein 
phosphatases (Kim et al., 2010). It would therefore be interesting to determine if PP2A 
occurs in complex with CNK1/MST2/Raf-1. Moreover, CNK1 was found to interact 
with Raf-1 and Src to activate ERK via pro-angiogenic vascular endothelial growth 
factor (VEGF) but not EGF; however B-Raf also binds CNK1 (Ziogas et al., 2005) 
which complicates the matter. It is evident that CNK1 involvement with MST2 and Raf-
1 regulation is highly complex and has seemingly paradoxical functions. Alternatively, 
scaffold protein functions have both positive and negative effects on signalling and 
therefore may fill the gap of some contradictory observations on this opposing Raf-
1:MST2 complex. 
 
 
Mapping the interaction domains of CNK1 
 
In line with this idea, mapping of the binding sites revealed a complex interaction. 
However, it is consistent with the scaffold property of CNK1 on its ability to bind 
proteins in its multidomain structure. Indeed, Raf-1, MST2 and RASSF1A each revealed 
several possible binding sites with strong affinity towards CNK1’s interacting domains. 
Although, binding regions are consistent with previous studies some previously 
undiscovered binding sites exhibited strong signals. For example, it was suggested that 
Raf-1 binds to the C-terminal of CNK1 (Rabizadeh et al., 2004). However, peptide array 
analysis indicates that Raf-1 also binds to CNK1 at several sites in the amino terminal 
region particularly in the SAM to PDZ domain region. Interestingly, Rabizadeh et al 
findings indicate that full-length CNK1 binds more strongly than the C-terminal region 
alone to Raf-1. Therefore, it could be argued that there may be regions in the amino 
terminal that may be crucial in Raf-1 binding. Interestingly, in Drosophila, the ability of 
Ras to activate Raf-1 strictly depends on SAM and CRIC domains of CNK (Douziech et 
al., 2007). It will be interesting to determine if such mechanism exist in mammalian 
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CNK1 as my results indicate several possible binding sites in these regions. Also, 
compared to previous reports that RASSF1A binds mostly to CRIC and PDZ of CNK1, 
my peptide screening data suggests that RASSF1A binds a wider region that comprises 
CRIC, PDZ and the PH domain and a few other strong residues at the C-terminal 
regions, particularly at the coiled-coil regions. Incidentally, it was suggested that 
RASSF1A functions as a scaffold protein as well, as it assembles multiple proteins and 
contains binding domains that are involved in protein-protein interactions and membrane 
association (Donninger et al., 2007). Therefore, it is not surprising that the data from 
peptide arrays indicate a strong affinity and wider span of binding sites compared to 
previous studies. 
 
Meanwhile, MST2 revealed for the first time in this study binding sites with a strong 
affinity at the proline-rich and PH domains of CNKI. Interestingly, proline-rich regions 
are often involved in complex protein association because of the rapid and non-specific 
nature of their interaction. Also, PH domains are involved in signal transduction 
particularly in recruiting proteins to specific cellular compartments (Williamson, 1994, 
Pawson, 1995). Of note, it is conceivable that MST2 binds to wide regions of CNK1 to 
enable protection from activation or cleavage of its N-terminal upon caspase activation 
which is supported from the peptide array data. 
 
 
A short motif within CNK1 is necessary in mediating Raf-1:MST2 
complex 
 
Upon further analysis of these peptide arrays, a short binding motif that is common to 
Raf-1, MST2 and RASSF1A was found and located at the regions spanning the Proline-
rich region and start of the PH domain of CNK1. A mutant construct substituting the 
S377 to Alanine or Aspartic Acid of the RKKSK motif of CNK1, provides evidence for 
a probable functional role of the proline-rich region of CNK1 in mediating the Raf-
1:MST2 complex. Of note, Akt phosphorylates Serine or Threonine residues in the motif 
RxRxxS/T (R= arginine, S = serine, T = threonine and x = any amino acid) containing 
proteins (Yaffe et al., 2001). The phosphorylation of its substrate will in many cases 
result in subsequent binding of 14-3-3 which also binds to matching consensus motif as 
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Akt. Regulation of this motif induces conformation, localisation and activate or inhibit 
intrinsic enzymatic of proteins in the complex (Aitken et al., 2002). As CNK1 has been 
implicated to interact with Akt or probably 14-3-3 through Raf-1 it will be interesting to 
test if RKKSK motif on CNK1 may be regulated as well as it is a potential 
phosphorylation or binding site of either proteins. However, a detailed binding 
characterisation of these mutations independently of Raf-1 and MST2 including 
RASSF1A will further confirm these findings.     
 
Interestingly, further analysis of the binding sites of Raf-1, MST2 and RASSF1A 
indicates overlapping binding residues on CNK1. It is conceivable that these proteins 
compete for binding to CNK1 in similar manner to how Raf-1 competes with RASSF1A 
to bind MST2 as their binding site was found to be overlapping at the coiled-coil region 
(SARAH) C-terminal of MST2 (Mattalanas et al., 2007). A report demonstrated that 
MST2 binds to the hSav scaffold protein that contains coiled-coil domains on their 
corresponding coiled-coil regions (Callus et al., 2006). In line with this, peptide arrays 
showed that MST2 and RASSF1A which both have coiled-coil domains bind to residues 
comprising the coiled-coil region of CNK1. Alternatively, as CNK1 contains several 
binding domains which suggest the possibility of CNK1 forming into a hetero-
oligomeric complex that may accommodate all three proteins, or even several molecules. 
For example, PDZ domains are known to interact with greater versatility as they can 
bind with C-terminal motifs, lipids, and other scaffolds, even with its internal peptide 
sequences therefore enabling dimerization and assembly of supra-molecular complexes 
(Harris and Lim, 2001; Pawson, 2007; Lee and Zheng, 2010).  
 
Finally, although highly speculative, it may be likely that distinct CNK1/MST2, 
CNK1/RASSF1A or CNK/Raf-1 complex may exist or perhaps a macromolecular 
complex of CNK1/MST2/RASSF1A/Raf-1 is also plausible that renders a more 
sophisticated mechanism. CNK1 contains four domains that function to facilitate multi-
protein-protein interactions, giving it the ability to exhibit allosteric, spatial and 
conformational regulation including formation of hetero-oligomeric complexes 
(Claperon and Thierren, 2007). Therefore, whether distinct complexes exist or supra-
molecular scaffolded complex exist for CNK1, similar to those that exist for the 
scaffolds MORG (Vomastek et al., 2008) or JIP1 scaffold (Willoughby et al., 2003) 
  130
which assembles opposing molecules as discussed in Chapter 3 remains to be 
determined. Moreover, a specific stepwise mechanism of CNK1-mediated Raf-1:MST2 
complex is yet to be determined and existence of other mechanisms yet to be identified 
cannot be rule out. However, the findings suggest that CNK1 may play a crucial role in 
the coordination of both opposing kinases in response to proliferative or apoptotic 
stimuli. 
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CHAPTER 5 
 
 
Final Discussion 
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Final Discussion 
 
 
Understanding the mechanisms that regulate signals critical for cell growth or apoptosis 
is essential in controlling diseases like cancer. Cells have the ability to control signals 
that they come across and, dependent on this environment, this response determines their 
fate. Maintenance of these signals that promote cell survival or prevent apoptosis is 
therefore an important aspect in the instigation of tumourigenesis (Hanahan and 
Weinberg, 2000).  
 
Indeed, numerous evidence has shown that the balance of the intensity and duration 
between apoptotic and survival signals transmitted by the different signalling molecules 
such as the MAPK module mediated by scaffold proteins is a determinant in the decision 
whether a cell survives or undergoes apoptosis (Murphy and Blenis, 2006). It is not 
surprising, as MAP kinase signalling is heavily involved in mechanisms that regulate 
activation of key oncogenes and tumour suppressors as well as specificity and 
amplification of signal transduction, as described in Chapter 1. In addition, the spatial 
and temporal organisation of different molecules within the cell is an essential step in 
coordinating the many distinct activities carried out by the cell in response to an array of 
stimuli (Mor and Phillips, 2006). In an increasing number of biological signalling 
processes that are elucidated, scaffold proteins have been found to play a central role in 
physically assembling the relevant molecular components to carry-out these many 
diverse activities (Morrison and Davis, 2003; Kolch, 2005). 
 
The aim of this thesis was to examine the role of CNK1 in the regulation of proto-
oncogene Raf-1 and tumour-suppressor MST2. First, I have shown that CNK1 manifests 
a prototypical concentration-dependent manner by mediating the interaction of Raf-1 
and MST2 under cellular stress conditions by serum starvation of cells. Given the role of 
scaffold proteins to assemble different proteins, the concentration of a scaffold needs to 
be titred or at an optimal concentration of the components it binds, therefore high 
concentration of scaffolds will dilute out the components (Levchenko, 2000). Consistent 
with this, at intermediate CNK1 concentrations Raf-1 and MST2 form a complex, 
thereby allowing Raf-1, independent of its kinase activity, to inhibit MST2 
  133
phosphorylation. This is crucial for its activation, and therefore MST2 binding to Raf-1 
leads to reduced apoptosis of cells under cellular stress conditions. However, at higher 
expression of CNK, Raf-1 and MST2 dissociate, therefore freeing MST2 from the 
inhibitory function of Raf-1, which results in its phosphorylation and induction of 
apoptosis. This dissociation of the CNK1-mediated Raf-1:MST2 complex results in the 
association of MST2 with its substrate LATS1, suggesting activation of downstream 
pro-apoptotic Hippo signalling. The requirement of CNK1 in the mediation of Raf-
1:MST2 complex formation was demonstrated further by depleting CNK1 using RNAi. 
Depletion of CNK1 impaired Raf-1 and MST2 interaction, with a concomitant 
enhancement of MST2 kinase activity and increased MST2/LATS1 interaction, 
sensitising cells to growth-withdrawal induced apoptosis. Moreover, co-siRNA 
experiments of MST2 and CNK1 prevented cells from apoptosis indicating that CNK1-
mediated apoptosis is dependent on tumour suppressor Hippo/MST2 signalling. Whereas 
co-siRNA of CNK1 and Raf-1 markedly induced apoptosis compared to control and 
depletion of Raf-1 alone which suggest that Raf-1 requires CNK1 to link with MST2 to 
exert its inhibitory role. Therefore, at physiological levels of CNK1 in Hela cells, it may 
protect the cells from apoptosis however at a very high expression it may render the cells 
to be more sensitive towards programmed cell death. 
 
Second, this role of CNK1 was extended in Fas death receptor signalling. I have shown 
for the first time that MST2 and Raf-1 endogenously interact with CNK1 and are 
preassembled prior to Fas stimulation. This may explain why MST2 and Raf-1 
interaction are enhanced in quiescent cells and dissociate upon cellular stress and 
apoptotic stimulation. Moreover, the rapid dissociation of MST2 from Raf-1 after Fas 
stimulation may be delayed or rescued by CNK1 in a time-dependent manner which 
indicates a temporal regulation role of CNK1. The decision for cells to undergo 
apoptosis is determined by the integration of multiple survival and death signalling 
molecules (Utz and Anderson, 2000). Therefore, through protein–protein interactions, 
CNK1 may directly act on a critical component of the cellular proapoptotic signalling 
machinery by preventing caspase activation or cleavage of MST2 by compartmentalising 
a Raf-1:MST2 inhibitory complex. 
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Third, I have shown that CNK1 may play a role in the mediation of Raf-1 and MST2 
interaction in mitogenic conditions. Importantly, I have shown for the first time that 
MST2, Raf-1 and CNK1 are preassembled prior to mitogenic stimulation, which may 
explain why Raf-1 and MST2 interaction are also disrupted by mitogenic stimulation. 
These findings indicate a CNK1-mediated interaction of Raf-1:MST2 dependent of the 
type and duration of mitogenic stimulants.  
 
Fourth, I have mapped possible binding sites of Raf-1, MST2 and RASSF1A on CNK1 
by peptide array, which confirms previous reports but also revealed novel binding sites 
that suggest complex binding mechanisms. Consistent with this, multidomain scaffold 
proteins have been demonstrated to assemble different molecules and coordinate 
complex mechanisms such as conformational, kinase activities and forming large hetero-
oligomeric complexes, and are themselves target of regulation (Ebisuya et al., 2005; 
Good et al., 2011).    
 
Lastly, a short common binding motif of Raf-1, MST2 and RASSF1A to CNK1 revealed 
from the peptide array data, that it may have an important functional role in mediating 
Raf-1 and MST2 interaction, or RASSF1A which suggests a scaffold role in the 
Hippo/MST2 apoptotic signalling. Moreover, mutation of a Serine residue alters Raf-1 
and MST2 binding to CNK1, further supporting the significance of this motif. 
 
 
 
Conclusion 
 
In conclusion, scaffold proteins are believed to confer specificity in signal transduction 
by their ability to assemble a set of multiple binding partners into a pathway-dedicated 
signalling complex dependent to a particular stimulus and duration, including regulation 
of spatial and temporal cell signalling processes (Kolch, 2005; Bhattacharyya et al., 
2006; Saito, 2010; Malleshaiah et al., 2010). CNK1 protein is characterised as a scaffold 
protein due to its intrinsic multidomain structure and has been demonstrated to function 
as a scaffold protein by binding to different proteins involved in several signalling 
pathways (Fritz and Radziwill, 2011). This thesis has provided evidence in support of 
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the direct role of CNK1 as a scaffold protein by its ability to mediate the Raf-1:MST2 
complex. Moreover, the work presented here contributes to the current understanding of 
the mechanisms underlying the regulation of the opposing proto-oncogene Raf-1 and 
tumour suppressor MST2 interaction via apoptotic signals as well as growth-promoting 
signals. Further study of CNK1’s scaffold function is likely to prove fruitful for 
understanding how cells coordinate and shape the response to their survival or own 
demise, further contributing to the understanding of cancer cell expansion and 
progression.  
 
 
 
CNK1 Model 
 
 
Figure 4.L.  CNK1 Model. A. CNK1 preassembles a complex of interacting proteins in 
quiescent cells. Upon stimulus, CNK1 facilitates the disassembly of the complex and 
induces conformation of appropriate interacting signaling modules to carry-out their 
function specific to the stimulus. B. At low levels of CNK1, regulation of its client 
proteins is limiting. At optimum levels of CNK1, an efficient control of the complex can 
be facilitated, however at higher levels of CNK1, client proteins are diluted and 
therefore regulation of their signaling output is dissipated.   
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Future Directions 
 
The cellular outcomes of CNK1 scaffold proteins are as divergent and complex. The 
challenges ahead include understanding at systems level, of how growth factor signalling 
and apoptotic signalling makes use of a scaffold protein, possibly such as those of 
CNK1’s circuitry, which is may be crucial for cellular decisions that determine cell fate. 
Hence, the scaffold features of proteins in cell signalling are now starting to be 
appreciated. As specific compounds that target a single molecular cellular target in many 
cases will likely fail for complex diseases like cancer, it has been proposed that 
molecular networks associated with a disease may be an alternative target for 
intervention (Pawson and Linding, 2008). This strategy involves a synthetic biology 
approach that aims to engineer or rewire (i.e. changing assembly of protein kinases) 
signalling to change the response of cellular pathways, for example by manipulating 
multidomain proteins to change the response of cells from mitogenic signals to cell 
death signals (Howard et al., 2003). Nevertheless, accumulating evidence indicates that 
the properties of multidomain structures such as that of scaffold proteins may prove 
valuable in understanding important mechanisms for controlling signal transduction 
pathways and may be exploited for diverse therapeutic and biotechnological 
applications. 
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